<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Subst Abuse Rehabil</journal-id><journal-id journal-id-type="iso-abbrev">Subst Abuse Rehabil</journal-id><journal-id journal-id-type="pmc-domain-id">2178</journal-id><journal-id journal-id-type="pmc-domain">sar</journal-id><journal-id journal-id-type="publisher-id">sar</journal-id><journal-title-group><journal-title>Substance Abuse and Rehabilitation</journal-title></journal-title-group><issn pub-type="epub">1179-8467</issn><publisher><publisher-name>Dove Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11954470</article-id><article-id pub-id-type="pmcid-ver">PMC11954470.1</article-id><article-id pub-id-type="pmcaid">11954470</article-id><article-id pub-id-type="pmcaiid">11954470</article-id><article-id pub-id-type="pmid">40162321</article-id><article-id pub-id-type="doi">10.2147/SAR.S516138</article-id><article-id pub-id-type="publisher-id">516138</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Initiation and Dosing of Extended-Release Buprenorphine: A Narrative Review of Emerging Approaches for Patients Who Use Fentanyl</article-title><alt-title alt-title-type="running-authors">Lee et al</alt-title><alt-title alt-title-type="running-title">Lee et al</alt-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Lee</surname><given-names initials="KW">Kenneth W</given-names></name><xref rid="aff0001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="an0001" ref-type="corresp"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mead</surname><given-names initials="A">Annabel</given-names></name><xref rid="aff0002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ghauri</surname><given-names initials="I">Imran</given-names></name><xref rid="aff0003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hollett</surname><given-names initials="B">Bruce</given-names></name><xref rid="aff0004" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Drolet</surname><given-names initials="M">Martine</given-names></name><xref rid="aff0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kozicky</surname><given-names initials="JM">Jan-Marie</given-names></name><xref rid="aff0005" ref-type="aff">
<sup>5</sup>
</xref></contrib><aff id="aff0001"><label>1</label><institution>Department of Family Medicine, Department of Psychiatry, Western University</institution>, <addr-line>London</addr-line>, <addr-line>ON</addr-line>, <country>Canada</country></aff><aff id="aff0002"><label>2</label><institution>Correctional Health Services, BC Mental Health and Substance Use Services</institution>, <addr-line>Vancouver</addr-line>, <addr-line>BC</addr-line>, <country>Canada</country></aff><aff id="aff0003"><label>3</label><institution>Alberta Health Services</institution>, <addr-line>Calgary</addr-line>, <addr-line>AB</addr-line>, <country>Canada</country></aff><aff id="aff0004"><label>4</label><institution>Memorial University of Newfoundland</institution>, <addr-line>St. John&#8217;s</addr-line>, <addr-line>NL</addr-line>, <country>Canada</country></aff><aff id="aff0005"><label>5</label><institution>Indivior</institution>, <addr-line>Montreal</addr-line>, <addr-line>QC</addr-line>, <country>Canada</country></aff></contrib-group><author-notes><corresp id="an0001">Correspondence: Kenneth W Lee, <institution>London RAAM Clinic</institution>, <addr-line>Suite 260, 200 Queens Avenue</addr-line>, <addr-line>London</addr-line>, <addr-line>ON</addr-line>, <addr-line>N6A 1J3</addr-line>, <country>Canada</country>, <phone content-type="general">Tel +1 519 280 7790</phone>, Email ken.lee@sjhc.london.on.ca</corresp></author-notes><pub-date pub-type="epub"><day>25</day><month>3</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>16</volume><issue-id pub-id-type="pmc-issue-id">480623</issue-id><fpage>71</fpage><lpage>82</lpage><history><date date-type="received"><day>07</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>09</day><month>3</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>25</day><month>03</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>29</day><month>03</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-04-05 03:25:37.420"><day>05</day><month>04</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 Lee et al.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Lee et al.</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/3.0/</ali:license_ref><license-p>This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution &#8211; Non Commercial (unported, v3.0) License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="sar-16-71.pdf"/><abstract><title>Abstract</title><p>Individuals with Opioid Use Disorder (OUD) who use fentanyl are at high risk of mortality due to opioid-related overdose. While buprenorphine extended-release (BUP-XR) may reduce this risk, there is a need to optimize clinical practice with BUP-XR to overcome barriers to treatment initiation and retention in patients who use fentanyl. Through a narrative review of evidence from peer-reviewed publications and conference abstracts, this article provides an overview of current novel initiation and dosing strategies for BUP-XR in patient populations with confirmed or presumed use of fentanyl. Evidence in this area is rapidly emerging with multiple studies describing BUP-XR initiation prior to 7-day stabilization on transmucosal buprenorphine (TM-BUP). Results from a randomized controlled study indicate that initiating BUP-XR following a single TM-BUP dose is noninferior to standard initiation in terms of treatment retention at injection 2, with similar rates of precipitated withdrawal and adverse events, and this protocol is now included in the approved prescribing information in the USA. While additional &#8220;macro/high-dose&#8221; or &#8220;micro/low-dose&#8221; and &#8220;direct dose&#8221; induction approaches have also been reported, evidence for these is limited to small uncontrolled studies or case reports. Consistent with evidence from studies of TM-BUP, which suggests individuals who use fentanyl may require higher maintenance doses in order to be retained in treatment, administrative and observational data suggests that use of the 300-mg maintenance dose, shortened intervals between doses, and supplemental TM-BUP may be feasible approaches to increase buprenorphine exposure in patients with ongoing symptoms and improve retention. Evidence in this area is rapidly evolving, and many of these strategies are increasingly being adopted clinically and incorporated into clinical guidelines. Further research should incorporate increased sample sizes, broader and more consistent outcome measurement, and increased duration of follow-up to facilitate more robust evaluation of efficacy and safety as well as increase comparability between studies.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>opioid use disorder</kwd><kwd>extended-release buprenorphine</kwd><kwd>long-acting buprenorphine</kwd><kwd>BUP-XR</kwd><kwd>fentanyl</kwd></kwd-group><counts><fig-count count="0"/><table-count count="2"/><ref-count count="73"/><page-count count="12"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s0001"><title>Introduction</title><p>The opioid crisis continues to be a major cause of mortality across North America, with 81,806 individuals dying from related opioid overdose in the United States (US)<xref rid="cit0001" ref-type="bibr">1</xref> and 7792 in Canada<xref rid="cit0002" ref-type="bibr">2</xref> in 2022. A significant driver of this is the surge of high-potency synthetic opioids in the illicit opioid market, with over 80% of opioid-related deaths in both countries attributed to fentanyl.<xref rid="cit0001" ref-type="bibr">1</xref>,<xref rid="cit0002" ref-type="bibr">2</xref></p><p>The majority of people who die from an opioid overdose have opioid use disorder (OUD), with only a subset receiving treatment prior to their death,<xref rid="cit0003" ref-type="bibr">3</xref> despite evidence for various treatments in reducing mortality in the fentanyl era.<xref rid="cit0004" ref-type="bibr">4</xref>,<xref rid="cit0005" ref-type="bibr">5</xref> Extended-release buprenorphine (BUP-XR, SUBLOCADE<sup>&#174;</sup>) is a monthly subcutaneous buprenorphine injection available in both the USA and Canada, where fentanyl dominates the illicit drug supply. BUP-XR was developed to deliver sustained therapeutic levels of buprenorphine,<xref rid="cit0006" ref-type="bibr">6</xref>,<xref rid="cit0007" ref-type="bibr">7</xref> avoiding fluctuations from inconsistent daily dosing that could contribute to opioid withdrawal, craving, and relapse.<xref rid="cit0007" ref-type="bibr">7</xref> In a small open-label, cross over pharmacodynamic study using intravenous buprenorphine, sustained buprenorphine levels consistent with those delivered by BUP-XR were associated with reduced risk of respiratory depression from fentanyl,<xref rid="cit0008" ref-type="bibr">8</xref>,<xref rid="cit0009" ref-type="bibr">9</xref> and in clinical practice, BUP-XR treatment has also been associated with lower rates of nonfatal overdose compared to treatment with transmucosal buprenorphine (TM-BUP) or methadone (MET).<xref rid="cit0010" ref-type="bibr">10</xref></p><p>The Phase 3 pivotal trial for BUP-XR<xref rid="cit0006" ref-type="bibr">6</xref> was conducted across the USA in 2015, just as fentanyl was emerging in northeastern states<xref rid="cit0011" ref-type="bibr">11</xref> and prior to widespread awareness of its unique clinical challenges. In addition to overdose risks associated with illicit fentanyl, clinical experience suggests that, compared with heroin use, fentanyl use may lead to more rapid onset, severe, or protracted withdrawal symptoms,<xref rid="cit0012" ref-type="bibr">12</xref> higher risk of precipitated opioid withdrawal (PW) during buprenorphine inductions,<xref rid="cit0013" ref-type="bibr">13</xref>,<xref rid="cit0014" ref-type="bibr">14</xref> and lower treatment retention.<xref rid="cit0015" ref-type="bibr">15</xref>,<xref rid="cit0016" ref-type="bibr">16</xref> These challenges have led to clinical guidelines and other consideration documents increasingly recommending a more flexible approach to treatment in patients who use fentanyl, including modifications to buprenorphine treatment initiation and maintenance dosing strategies.<xref rid="cit0017" ref-type="bibr">17&#8211;21</xref> Given the rapid evolution of clinical practice in this area, the objective of this narrative review is to describe the available literature on BUP-XR initiation and dosing strategies in the fentanyl era in order to better understand emerging clinical practice and inform future research needs.</p></sec><sec id="s0002"><title>Materials and Methods</title><p>We completed a search of peer-reviewed literature (PubMed) and conference abstracts (ProQuest) up to Aug 29, 2024, and provided a narrative review of those which reported initiation and dosing of BUP-XR in populations exposed to fentanyl, with findings discussed in the context of recommended use established in the registrational trials for BUP-XR and included in the product labels.<xref rid="cit0022" ref-type="bibr">22</xref>,<xref rid="cit0023" ref-type="bibr">23</xref></p><p>Multiple search terms were used to capture BUP-XRrelated terminology (eg, BUP-XR, long-acting buprenorphine, SUBLOCADE<sup>&#174;</sup>), with studies and reports describing initiation and dosing of BUP-XR in patients with confirmed or presumed use of fentanyl included for narrative review. Given inconsistencies in identifying and reporting fentanyl use in earlier studies, based on drug seizure and overdose death reports, we presumed subjects using illicit opioids in the eastern, midwest, and southern USA after 2013<xref rid="cit0024" ref-type="bibr">24</xref> and in the western USA<xref rid="cit0025" ref-type="bibr">25</xref> and Canada after 2017<xref rid="cit0026" ref-type="bibr">26</xref> were exposed to fentanyl unless stated otherwise. Given the limited instances of fentanyl in the illicit drug supplies of Australia<xref rid="cit0027" ref-type="bibr">27</xref> and Europe,<xref rid="cit0028" ref-type="bibr">28</xref> publications from these regions were presumed not to include subjects exposed to fentanyl, unless this was specifically noted.</p><p>Studies describing alternate BUP-XR formulations not available in both Canada and the USA (eg, BUVIDAL<sup>&#174;</sup>, BRIXADI<sup>&#174;</sup>, PROPUBHINE<sup>&#174;</sup>) were not reviewed, as these formulations would be subject to different initiation and dosing protocols.</p></sec><sec id="s0003"><title>Results</title><sec id="s0003-s2001"><title>BUP-XR Initiation Protocols</title><p>In the initial registration trials for BUP-XR, participants were first inducted and stabilized with 8 to 24 mg TM-BUP daily for 7 to 14 days before initiating BUP-XR.<xref rid="cit0006" ref-type="bibr">6</xref> The purpose of this initiation period was to ensure tolerance and clinical response to buprenorphine (ie, reduction in withdrawal and cravings) prior to transitioning to a long-acting buprenorphine product. To complete TM-BUP induction, patients need to abstain from fentanyl or other opioids for a minimum period and be in at least moderate withdrawal prior to receipt of the first dose to reduce risk of PW,<xref rid="cit0029" ref-type="bibr">29</xref> a requirement which may limit the ability of many individuals to access this treatment.<xref rid="cit0030" ref-type="bibr">30</xref> Even after completing induction, patients who use fentanyl may experience further barriers with adhering to daily treatment for the required period prior to transitioning to BUP-XR.<xref rid="cit0031" ref-type="bibr">31</xref>&#8211;<xref rid="cit0033" ref-type="bibr">33</xref> Given these issues, the necessity of undergoing a standard TM-BUP induction and completing the recommended 7 days of treatment has been challenged by several clinical guidelines,<xref rid="cit0017" ref-type="bibr">17</xref>&#8211;<xref rid="cit0021" ref-type="bibr">21</xref> and multiple publications suggest that alternate induction protocols and/or a less than 7-day stabilization may be feasible when clinically indicated.<xref rid="cit0031" ref-type="bibr">31&#8211;50</xref></p><p>While there is significant variation in the approaches reported across different studies, in general alternate BUP-XR initiation strategies may be categorized as rapid/test, macro/high-dose, micro/low-dose, or direct dose protocols (<xref rid="t0001" ref-type="table">Table 1</xref>). There was considerable variability across studies in outcomes reported, including rate of initiation completion, incidence of PW, severity of withdrawal symptoms, retention in treatment, opioid abstinence, health service utilization, and/ or adverse events.
<table-wrap position="float" id="t0001" orientation="portrait"><label>Table 1</label><caption><p>BUP-XR Initiation Protocols with &lt;7-Day TM-BUP Stabilization Periods Described in Patients Using Fentanyl</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Citation</th><th rowspan="1" colspan="1">Location&#160;</th><th rowspan="1" colspan="1">Study Description</th><th rowspan="1" colspan="1">Day 1</th><th rowspan="1" colspan="1">Day 2</th><th rowspan="1" colspan="1">Day 3</th><th rowspan="1" colspan="1">Day 4</th><th rowspan="1" colspan="1">Day 5</th></tr></thead><tbody><tr><td colspan="8" rowspan="1">BUP-XR initiated without any immediate prior TM-BUP dose, in patients with previous exposure to TM-BUP</td></tr><tr><td rowspan="1" colspan="1">Wethern, 2023<xref rid="cit0031" ref-type="bibr">31</xref></td><td rowspan="1" colspan="1">Denver, Colorado, USA</td><td rowspan="1" colspan="1">Case study (n=2)</td><td rowspan="1" colspan="1">300 mg&#160;BUP-XR</td><td rowspan="2" colspan="4">&#160;</td></tr><tr><td rowspan="1" colspan="1">Mooney 2024<xref rid="cit0050" ref-type="bibr">50</xref></td><td rowspan="1" colspan="1">Portland, Oregan, USA</td><td rowspan="1" colspan="1">Case study (n=2)</td><td rowspan="1" colspan="1">300 mg&#160;BUP-XR</td></tr><tr><td colspan="8" rowspan="1">BUP-XR initiated after single TM-BUP dose</td></tr><tr><td rowspan="1" colspan="1">Hassman 2023<xref rid="cit0039" ref-type="bibr">39</xref></td><td rowspan="1" colspan="1">Berlin, NJ, USA</td><td rowspan="1" colspan="1">Open label, uncontrolled (n=26)</td><td rowspan="1" colspan="1">4 mg TM-BUP<break/>300 mg&#160;BUP-XR</td><td rowspan="3" colspan="4">&#160;</td></tr><tr><td rowspan="1" colspan="1">Ochalek, 2023<xref rid="cit0041" ref-type="bibr">41</xref></td><td rowspan="1" colspan="1">Richmond, VA, USA</td><td rowspan="1" colspan="1">Open label, uncontrolled (n=19)</td><td rowspan="1" colspan="1">4 mg TM-BUP<break/>300 mg&#160;BUP-XR</td></tr><tr><td rowspan="1" colspan="1">Shiwach 2024<xref rid="cit0014" ref-type="bibr">14</xref></td><td rowspan="1" colspan="1">Multiple Sites, Canada/ USA</td><td rowspan="1" colspan="1">Randomized controlled trial (n=489)</td><td rowspan="1" colspan="1">4 mg TM-BUP<break/>300 mg&#160;BUP-XR</td></tr><tr><td colspan="8" rowspan="1">BUP-XR initiated after macro/high-dose TM-BUP induction</td></tr><tr><td rowspan="1" colspan="1">Mariani, 2021<xref rid="cit0043" ref-type="bibr">43</xref></td><td rowspan="1" colspan="1">New York, NY, USA</td><td rowspan="1" colspan="1">Open label, uncontrolled (n=5)</td><td rowspan="1" colspan="1">24 mg TM-BUP (divided)<break/>300&#160;mg BUP-XR</td><td colspan="4" rowspan="1"/></tr><tr><td rowspan="1" colspan="1">Taylor 2024<xref rid="cit0032" ref-type="bibr">32</xref></td><td rowspan="1" colspan="1">Boston, MA, USA</td><td rowspan="1" colspan="1">Case study (n=1)</td><td rowspan="1" colspan="1">12mg IN-NAL<break/>16mg TM-BUP<break/>300&#160;mg BUP-XR</td><td rowspan="1" colspan="1"/><td colspan="3" rowspan="1"/></tr><tr><td rowspan="1" colspan="1">Kahan, 2023<xref rid="cit0034" ref-type="bibr">34</xref></td><td rowspan="1" colspan="1">Timmins, ON, Canada</td><td rowspan="1" colspan="1">Case study (n=2)</td><td rowspan="1" colspan="1">28&#8211;32 mg TM-BUP (divided)</td><td rowspan="1" colspan="1">32&#160;mg&#160;TM-BUP<break/>300 mg BUP-XR</td><td rowspan="2" colspan="3">&#160;</td></tr><tr><td rowspan="1" colspan="1">LeSaint 2024<xref rid="cit0044" ref-type="bibr">44</xref></td><td rowspan="1" colspan="1">San Francisco, CA, USA</td><td rowspan="1" colspan="1">Case study (n=1)</td><td rowspan="1" colspan="1">32mg TM-BUP (divided)</td><td rowspan="1" colspan="1">32 mg&#160;TM-BUP<break/>300 mg BUP-XR</td></tr><tr><td rowspan="2" colspan="1">Mariani, 2020<xref rid="cit0042" ref-type="bibr">42</xref></td><td rowspan="2" colspan="1">New York, NY, USA</td><td rowspan="2" colspan="1">Open label, uncontrolled (n=5)</td><td rowspan="2" colspan="1">10&#8211;24 mg TM-BUP (divided)</td><td rowspan="1" colspan="1">16&#8211;24mg TM-BUP (divided)<break/>300&#160;mg BUP-XR</td><td rowspan="1" colspan="1"/><td colspan="2" rowspan="1">&#160;</td></tr><tr><td rowspan="1" colspan="1">8&#8211;24mg TM-BUP (divided)</td><td rowspan="1" colspan="1">16&#160;mg TM-BUP (divided)<break/>300&#160;mg BUP-XR</td><td colspan="2" rowspan="1">&#160;</td></tr><tr><td colspan="8" rowspan="1">BUP-XR initiated after micro/low-dose TM-BUP induction</td></tr><tr><td rowspan="1" colspan="1">Azar 2024<xref rid="cit0048" ref-type="bibr">48</xref></td><td rowspan="1" colspan="1">Vancouver BC, Canada</td><td rowspan="1" colspan="1">Case study (n=2)</td><td rowspan="1" colspan="1">6 x 20 ug/h BUP TD patches</td><td rowspan="1" colspan="1">Additional 6 x 20 ug/h BUP TD patches</td><td rowspan="1" colspan="1">BUP-TD patches removed<break/>4mg TM-BUP<break/>300 mg BUP-XR</td><td colspan="2" rowspan="1"/></tr><tr><td rowspan="1" colspan="1">Azar, 2023<xref rid="cit0047" ref-type="bibr">47</xref></td><td rowspan="1" colspan="1">Vancouver, BC, Canada</td><td rowspan="1" colspan="1">Case study (n=1)</td><td rowspan="1" colspan="1">6 x 20 ug/h BUP TD patches</td><td rowspan="1" colspan="1">Additional 6 x 20 ug/h BUP TD patches</td><td rowspan="1" colspan="1">BUP-TD patches removed<break/>300&#160;mg BUP-XR</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">&#160;</td></tr><tr><td rowspan="1" colspan="1">Azar, 2020<xref rid="cit0046" ref-type="bibr">46</xref></td><td rowspan="1" colspan="1">Vancouver, BC, Canada</td><td rowspan="1" colspan="1">Case study (n=1)</td><td rowspan="1" colspan="1">3 mg TM-BUP (divided)</td><td rowspan="1" colspan="1">7 mg TM-BUP (divided)</td><td rowspan="1" colspan="1">8 mg TM-BUP</td><td rowspan="1" colspan="1">300 mg&#160;BUP-XR</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Gorham 2024<xref rid="cit0049" ref-type="bibr">49</xref></td><td rowspan="1" colspan="1">Kansas City, KS, USA</td><td rowspan="1" colspan="1">Case study (n=1)</td><td rowspan="1" colspan="1">1x10 ug/h BUP TD patch1mg TM-BUP bid</td><td rowspan="1" colspan="1">1x10 ug/h BUP TD patch1mg TM-BUP qid</td><td rowspan="1" colspan="1">1x10 ug/h BUP TD patch1mg TM-BUP 8x/d</td><td rowspan="1" colspan="1">1x10 ug/h BUP TD patch8mg TM-BUP</td><td rowspan="1" colspan="1">300mg BUP-XR</td></tr></tbody></table><table-wrap-foot><fn id="tfn0001"><p><bold>Abbreviations</bold>: BUP-XR, extended-release buprenorphine; IN, intranasal; BUP-TD, transdermal buprenorphine; TM-BUP, transmucosal buprenorphine.</p></fn></table-wrap-foot></table-wrap></p><sec id="s0003-s2001-s3001"><title>Rapid/Test Dose Induction</title><p>The largest volume of evidence for alternate BUP-XR initiation protocols is with rapid/test dose protocols that provide the first 300-mg BUP-XR injection 1 hour after a single 4-mg TM-BUP test dose. With this protocol, patients were required to have a Clinical Opioid Withdrawal Scale (COWS) score &#8805;8 prior to receiving TM-BUP. While initial pilot studies provided support for the feasibility of this approach for patients who use fentanyl in outpatient<xref rid="cit0039" ref-type="bibr">39</xref>,<xref rid="cit0040" ref-type="bibr">40</xref> and emergency department<xref rid="cit0041" ref-type="bibr">41</xref> settings, a recently completed randomized controlled trial (n=723; 77% fentanyl positive at baseline) has compared outcomes between this approach and the traditional TM-BUP induction and stabilization period.<xref rid="cit0014" ref-type="bibr">14</xref> In this study, rapid/test dose initiation was found to be noninferior to standard initiation in terms of treatment retention at injection 2 (62.8% vs 47.9% for fentanyl-positive subjects), with comparable rates of PW and other safety events between the two methods. While this protocol has been included in the updated prescribing information in the USA,<xref rid="cit0022" ref-type="bibr">22</xref> the Canadian product monograph still requires patients to undergo a standard induction and are stabilized for a minimum of 7 days on TM-BUP.<xref rid="cit0023" ref-type="bibr">23</xref></p></sec><sec id="s0003-s2001-s3002"><title>Macro/High-Dose Induction</title><p>Five reports examined the feasibility of BUP-XR initiation after a &#8220;macro&#8221; or &#8220;high&#8221; dose TM-BUP induction in a total of 14 patients, with no comparison of outcomes with standard approaches.<xref rid="cit0032" ref-type="bibr">32</xref>,<xref rid="cit0034" ref-type="bibr">34</xref>,<xref rid="cit0042" ref-type="bibr">42&#8211;44</xref> In the first case series, n=5 patients with heroin/fentanyl use and baseline COWS scores &gt;6 (range 10&#8211;16) received up to 24-mg TM-BUP in divided doses on Day 1 of induction, with the first 300-mg BUP-XR injection given on Day 2 (n=2) or Day 3 (n=3).<xref rid="cit0042" ref-type="bibr">42</xref> All participants completed initiation with no PW attributed to BUP-XR, although 2 participants were not able to attend the clinic on the second day of TM-BUP initiation due to severe withdrawal symptoms. In order to address this, a follow-up study was conducted where the BUP-XR injection was provided the same day as the initial TM-BUP induction. This open-label study included 5&#160;heroin/fentanyl using participants with COWS score &gt;6 (range 8&#8211;18) given 24-mg TM-BUP in 4 divided hourly doses, followed by a 300-mg BUP-XR injection that same day.<xref rid="cit0043" ref-type="bibr">43</xref> All patients completed initiation (ie, received the 300-mg injection) with no incidence of protracted PW. All 5 participants were retained for 3 months and received all 3 scheduled BUP-XR injections.</p><p>The application of a macro/high-dose protocol in emergency department (ED) settings has also been reported in 4 cases. In two reports,<xref rid="cit0032" ref-type="bibr">32</xref>,<xref rid="cit0044" ref-type="bibr">44</xref> 3 individuals with fentanyl use who presented to the ED in withdrawal received BUP-XR after stabilization with high-dose TM-BUP (28&#8211;32 mg in divided doses). An additional 32-mg TM-BUP was provided the following day, followed by a 300-mg BUP-XR injection. Both patients received their second BUP-XR injection in the community. In another report from an ED setting, a patient in spontaneous opioid withdrawal received 32-mg TM-BUP in divided doses, returned the next day for an additional 32-mg TM-BUP and a 300-mg BUP-XR injection.<xref rid="cit0042" ref-type="bibr">42</xref> In the fourth case, the patient underwent a macro/high-dose protocol after being in severe opioid withdrawal following overdose reversal by 12-mg intranasal naloxone. In this case, 16-mg TM-BUP was provided followed by 300-mg BUP-XR, although intervals between doses were not reported.<xref rid="cit0032" ref-type="bibr">32</xref></p></sec><sec id="s0003-s2001-s3003"><title>Micro/Low-Dose Induction</title><p>Five case reports of BUP-XR initiation in a total of six patients using fentanyl following 3 different &#8220;micro&#8221; or &#8220;low&#8221; buprenorphine dosing induction protocols were identified.<xref rid="cit0045" ref-type="bibr">45&#8211;49</xref> In the first case study, an individual using illicit fentanyl started a TM-BUP microdosing protocol in the community, receiving ascending twice daily doses with continued fentanyl use, starting with 0.5 mg administered as 0.25 mg twice daily on Day 1 and reaching a single 12-mg dose on Day 7; COWS scores were not reported.<xref rid="cit0045" ref-type="bibr">45</xref> Following the 12-mg dose, the patient experienced severe PW (COWS=18) that required management with additional TM-BUP and ketamine. The patient continued the induction, receiving 24-mg TM-BUP on Day 10 followed by BUP-XR.</p><p>In another case report, an adolescent with severe OUD and multiple recent overdoses underwent a more rapid micro-induction protocol.<xref rid="cit0046" ref-type="bibr">46</xref> TM-BUP was administered in an inpatient setting every 3&#160;hours for 3 days (a total of 3 mg on Day 1, 7 mg on Day 2, and 8 mg on Day 3), and 300-mg BUP-XR was administered on Day 4. Hydromorphone was administered orally on Days 1 and 2 (15 mg and 5 mg, respectively). This approach was well tolerated with minimal withdrawal symptoms and no signs of PW, though the patient did not return for a subsequent dose. In two additional reports by the same group,<xref rid="cit0047" ref-type="bibr">47</xref>,<xref rid="cit0048" ref-type="bibr">48</xref> BUP transdermal patches (BUP-TD) were used instead of TM-BUP, with 6, 20-ug/h patches added on Day 1, and an additional 6 on Day 2, with the patches removed and 300-mg BUP-XR given on Day 3, with or without an additional TM-BUP. To maintain low levels of withdrawal symptoms and cravings and prevent the patient from leaving the hospital to use illicit fentanyl, full agonists were provided during the induction. After receipt of BUP-XR, full agonists were discontinued and the patient received additional 2&#8211;4 mg TM-BUP as needed, up to a maximum of 32 mg for 1 day before being discharged. An additional case of BUP-TD micro/low-dose initiation to BUP-XR has also been reported applying a lower dose (1x10 ug/h) combined with TM-BUP in escalating doses.<xref rid="cit0049" ref-type="bibr">49</xref></p></sec><sec id="s0003-s2001-s3004"><title>Direct Dose Induction</title><p>In two conference abstracts, clinicians bypassed the use of TM-BUP prior to BUP-XR to overcome challenges with medication adherence.<xref rid="cit0031" ref-type="bibr">31</xref>,<xref rid="cit0050" ref-type="bibr">50</xref> In the first report, 2 youths received a BUP-XR injection &#8804;1 day after discontinuing fentanyl.<xref rid="cit0031" ref-type="bibr">31</xref> Neither case reported PW. Further details, including pre/post-treatment COWS scores and subsequent outcomes, were not reported. In the second, 2 individuals with prior unsuccessful TM-BUP initiation attempts received a BUP-XR injection within 1&#8211;4&#160;hours of most recent fentanyl use.<xref rid="cit0050" ref-type="bibr">50</xref> While not quantified, withdrawal symptoms reportedly worsened approximately 2h after the injection, continued throughout the first 24&#8211;48h, and resolved within 72h. Both patients continued to use illicit fentanyl for the first 48&#8211;72h of induction, and one also received additional TM-BUP (up to 40 mg/day).</p></sec></sec><sec id="s0003-s2002"><title>BUP-XR Dosing</title><sec id="s0003-s2002-s3001"><title>Maintenance Dose</title><p>After induction and stabilization on TM-BUP, participants in the registrational trials were transitioned to BUP-XR with two 300-mg starting doses, followed by 300-mg or 100-mg BUP-XR maintenance doses.<xref rid="cit0006" ref-type="bibr">6</xref> These 2 maintenance doses were selected in order to either maintain buprenorphine exposure levels from the initial doses (100-mg maintenance dose) or provide higher concentrations (300-mg maintenance dose) hypothesized to be necessary for some participants, based on their drug use history and clinical condition.<xref rid="cit0006" ref-type="bibr">6</xref> This hypothesis was supported by a subsequent secondary subgroup analysis, which found that while the 100-mg maintenance dose was equally effective in non-injecting participants, in participants with a history of injecting illicit opioids, the 300-mg maintenance dose was associated with higher rates of treatment retention and opioid abstinence.<xref rid="cit0051" ref-type="bibr">51</xref> While the recommended maintenance dose for BUP-XR in both the USA<xref rid="cit0022" ref-type="bibr">22</xref> and Canada<xref rid="cit0023" ref-type="bibr">23</xref> is 100 mg monthly, it may be increased to 300 mg monthly based on clinical need.</p><p>Administrative data shows that rates of utilization of the 300-mg maintenance dose in patients with presumed exposure to fentanyl ranged from 19% in a commercially insured USA cohort in 2018<xref rid="cit0052" ref-type="bibr">52</xref> to 47.4% in a Canadian cohort from 2020 to 2022.<xref rid="cit0036" ref-type="bibr">36</xref> Consistent with this, individual programs reported rates of 300-mg maintenance dose from &#8805;24%&#8211;71%,<xref rid="cit0035" ref-type="bibr">35</xref>,<xref rid="cit0053" ref-type="bibr">53&#8211;59</xref> and 90% of patients in a correctional facility received the 300-mg maintenance dose (<xref rid="t0002" ref-type="table">Table 2</xref>).<xref rid="cit0060" ref-type="bibr">60</xref> The clinical rational for the 300-mg dose selection was discussed as being in relation to ongoing withdrawal or cravings.<xref rid="cit0057" ref-type="bibr">57</xref>,<xref rid="cit0059" ref-type="bibr">59</xref>,<xref rid="cit0060" ref-type="bibr">60</xref> Only one study maintained that all patients on the 100-mg maintenance dose; however, in this sample, only 7% of subjects reported that fentanyl was their opioid of choice, versus &gt;50% prescription opioids.<xref rid="cit0053" ref-type="bibr">53</xref>
<table-wrap position="float" id="t0002" orientation="portrait"><label>Table 2</label><caption><p>Proportion of Subjects Receiving 300-mg Maintenance Dose</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Citation</th><th rowspan="1" colspan="1">Location</th><th rowspan="1" colspan="1">Setting</th><th rowspan="1" colspan="1">N</th><th rowspan="1" colspan="1">% Exposed to Fentanyl</th><th rowspan="1" colspan="1">% Receiving 300-mg Dose</th><th rowspan="1" colspan="1">Treatment Month</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Griffith 2022<xref rid="cit0053" ref-type="bibr">53</xref></td><td rowspan="1" colspan="1">Little Rock, AR, USA</td><td rowspan="1" colspan="1">Veterans Affairs Addiction Clinic</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">Not stated. 7% reported fentanyl as opioid of choice; 7% hydrocode, 20% oxycodone, 20% heroin</td><td rowspan="1" colspan="1">0<sup>a</sup></td><td rowspan="1" colspan="1">Up to 12<sup>b</sup></td></tr><tr><td rowspan="3" colspan="1">Morgan 2021<xref rid="cit0052" ref-type="bibr">52</xref></td><td rowspan="3" colspan="1">National Sample, USA</td><td rowspan="3" colspan="1">Commercially Insured Cohort</td><td rowspan="3" colspan="1">204</td><td rowspan="3" colspan="1">Not stated.</td><td rowspan="1" colspan="1">26</td><td rowspan="1" colspan="1">3</td></tr><tr><td rowspan="1" colspan="1">19</td><td rowspan="1" colspan="1">4</td></tr><tr><td rowspan="1" colspan="1">19</td><td rowspan="1" colspan="1">5</td></tr><tr><td rowspan="1" colspan="1">Lee 2021<xref rid="cit0054" ref-type="bibr">54</xref></td><td rowspan="1" colspan="1">London, ON, Canada</td><td rowspan="1" colspan="1">Rapid Access Clinic</td><td rowspan="1" colspan="1">75</td><td rowspan="1" colspan="1">44% reported fentanyl as opioid of choice, 4% heroin, 61% other</td><td rowspan="1" colspan="1">24.2</td><td rowspan="1" colspan="1">Not stated</td></tr><tr><td rowspan="1" colspan="1">Lee 2023<xref rid="cit0010" ref-type="bibr">10</xref></td><td rowspan="1" colspan="1">BC and ON, Canada</td><td rowspan="1" colspan="1">Addiction Clinics</td><td rowspan="1" colspan="1">128</td><td rowspan="1" colspan="1">Approximately 20% had UDS positive for fentanyl at month 1</td><td rowspan="1" colspan="1">31</td><td rowspan="1" colspan="1">6</td></tr><tr><td rowspan="1" colspan="1">Deng 2023<xref rid="cit0055" ref-type="bibr">55</xref></td><td rowspan="1" colspan="1">Vancouver, BC, Canada</td><td rowspan="1" colspan="1">Low-threshold Addiction Clinic</td><td rowspan="1" colspan="1">47</td><td rowspan="1" colspan="1">68.1% reported fentanyl as opioid of choice.</td><td rowspan="1" colspan="1">38.3</td><td rowspan="1" colspan="1">3</td></tr><tr><td rowspan="2" colspan="1">Peckham 2021<xref rid="cit0035" ref-type="bibr">35</xref></td><td rowspan="2" colspan="1">Boston, MA, USA</td><td rowspan="2" colspan="1">Low-threshold Addiction Clinic</td><td rowspan="2" colspan="1">40</td><td rowspan="2" colspan="1">97.5% self-reported heroin/ fentanyl use; 2.5% prescription opioid use</td><td rowspan="1" colspan="1">53.8</td><td rowspan="1" colspan="1">3</td></tr><tr><td rowspan="1" colspan="1">38.5</td><td rowspan="1" colspan="1">4</td></tr><tr><td rowspan="1" colspan="1">Galati 2023<xref rid="cit0056" ref-type="bibr">56</xref></td><td rowspan="1" colspan="1">St Louis, MO, USA</td><td rowspan="1" colspan="1">Women&#8217;s Health Clinic</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">26.7% UDS positive for fentanyl during BUP-XR treatment</td><td rowspan="1" colspan="1">50.0</td><td rowspan="1" colspan="1">4&#8211;22</td></tr><tr><td rowspan="1" colspan="1">Heil 2023<xref rid="cit0037" ref-type="bibr">37</xref></td><td rowspan="1" colspan="1">Camden, NJ, USA</td><td rowspan="1" colspan="1">Addiction Clinic</td><td rowspan="1" colspan="1">108</td><td rowspan="1" colspan="1">88.8% self-reported history of heroin/ fentanyl use</td><td rowspan="1" colspan="1">70.8</td><td rowspan="1" colspan="1">3&#8211;6<sup>b</sup></td></tr><tr><td rowspan="1" colspan="1">Hanley 2023<xref rid="cit0058" ref-type="bibr">58</xref></td><td rowspan="1" colspan="1">Boston, MA, USA</td><td rowspan="1" colspan="1">Outpatient Clinic</td><td rowspan="1" colspan="1">208</td><td rowspan="1" colspan="1">Not stated</td><td rowspan="1" colspan="1">70.8</td><td rowspan="1" colspan="1">At least 3</td></tr><tr><td rowspan="1" colspan="1">Cotton 2022<xref rid="cit0057" ref-type="bibr">57</xref></td><td rowspan="1" colspan="1">Seattle, WA, USA</td><td rowspan="1" colspan="1">Veterans Affairs Addiction Clinic</td><td rowspan="1" colspan="1">26</td><td rowspan="1" colspan="1">Not stated. Clinically and medically complex.</td><td rowspan="1" colspan="1">77</td><td rowspan="1" colspan="1">Up to 10<sup>b</sup></td></tr><tr><td rowspan="1" colspan="1">Martin 2022<xref rid="cit0060" ref-type="bibr">60</xref></td><td rowspan="1" colspan="1">Rhode Island, USA</td><td rowspan="1" colspan="1">Correctional Facility</td><td rowspan="1" colspan="1">54</td><td rowspan="1" colspan="1">Not stated</td><td rowspan="1" colspan="1">90</td><td rowspan="1" colspan="1">At least 2</td></tr></tbody></table><table-wrap-foot><fn id="tfn0002"><p><bold>Notes</bold>: <sup>a</sup>Methods state 100-mg maintenance dose protocol used for all. <sup>b</sup>Breakdown not given.</p></fn><fn id="tfn0003"><p><bold>Abbreviations</bold>: BUP-XR, extended-release buprenorphine; MET, methadone; TM-BUP, transmucosal buprenorphine/naloxone; UDS, urine drug screen.</p></fn></table-wrap-foot></table-wrap></p><p>Currently, there is only one study available comparing outcomes between patients who receive the 100-mg versus 300-mg maintenance dose.<xref rid="cit0055" ref-type="bibr">55</xref> In this study, patients at a low-barrier rapid access addiction clinic who were naturalistically treated with the 300-mg maintenance dose at month three had greater retention than those who received the 100-mg dose, over the 23-month study period. Active fentanyl use was noted in 65.5% who received the 100-mg as the third dose and in 72.2% who received 300-mg. A randomized trial comparing outcomes between the 100-mg and 300-mg maintenance dose in high-risk individuals with OUD, including those who use fentanyl, is currently underway.<xref rid="cit0061" ref-type="bibr">61</xref></p></sec><sec id="s0003-s2002-s3002"><title>Alternate Dosing Intervals</title><sec id="s0003-s2002-s3002-s4001"><title>Accelerated Dosing</title><p>In the registrational trials, BUP-XR was administered monthly with 26&#8211;30 days between subsequent doses.<xref rid="cit0006" ref-type="bibr">6</xref> In the commercially insured USA cohort, which includes patients with presumed exposure to fentanyl, a subset of participants received more frequent, off-label, dosing: 14% of BUP-XR doses (n=44) were provided &lt;26 days since the prior administration (for those, median 23 days, range 14&#8211;25 days), though rationale for this, or timing during BUP-XR treatment was not reported.<xref rid="cit0052" ref-type="bibr">52</xref> Likewise, the analysis of Ontario administrative data shows a median dosing interval of 28 days, with 15.9% of injections being &lt;26 days apart (n=2141), including 2.2% &lt;14 days (n = 295).<xref rid="cit0036" ref-type="bibr">36</xref> While the safety and tolerability of providing the second 300-mg dose a week after the first has been supported by a post-marketing registrational study;<xref rid="cit0014" ref-type="bibr">14</xref> there are no studies comparing outcomes between subjects who receive an accelerated versus standard dosing schedule. The approved use for BUP-XR for both USA<xref rid="cit0022" ref-type="bibr">22</xref> and Canada<xref rid="cit0023" ref-type="bibr">23</xref> outlines monthly dosing, with a minimum 26 days between doses; however, the updated prescribing information in the USA does allow for the second 300-mg dose to be provided one week after the first injection.</p></sec><sec id="s0003-s2002-s3002-s4002"><title>Delayed Dosing</title><p>In the registrational trials, delays of dosing of up to 2&#160;weeks (ie, 6&#160;weeks between injections) were permitted, with participants discontinued from the study if presenting beyond this period for a follow-up injection.<xref rid="cit0006" ref-type="bibr">6</xref> Similarly, the BUP-XR product labels in the USA<xref rid="cit0022" ref-type="bibr">22</xref> and Canada<xref rid="cit0023" ref-type="bibr">23</xref> outline that unavoidable occasional delays in dosing up to 2&#160;weeks are not expected to have a clinically significant impact on treatment effect. In the USA commercially insured cohort with presumed fentanyl use, 12% of BUP-XR injections (n=37) occurred beyond the approved 6-week time frame (median 83 days, range 47&#8722;128 days).<xref rid="cit0052" ref-type="bibr">52</xref> In a claims level analysis, Ontario data showed that 4.1% of doses (n=549) were dispensed &gt;44 days after the previous injection, and when defining treatment discontinuation as &gt;56 days between doses, found that 32.3% who discontinued BUP-XR were subsequently re-initiated. In 50% of instances, re-initiation occurred 29&#8211;56 days after the initial discontinuation (ie, 3&#8211;5 months after their last injection).<xref rid="cit0036" ref-type="bibr">36</xref> A retrospective study of 26 veterans reported 70% of subjects received at least one delayed dose,<xref rid="cit0057" ref-type="bibr">57</xref> consistent with data from a rapid access clinic where only 40% of long-term patients received their injection on time.<xref rid="cit0054" ref-type="bibr">54</xref> In this setting, participants who presented longer than 8&#160;weeks between injections were re-initiated on TM-BUP (minimum 8 mg) for 1&#160;week prior to restarting BUP-XR, as part of a flexible re-entry program. Similarly, a pilot program of 108 participants in the correctional setting also permitted participants to restart BUP-XR, though specific protocols were not discussed.<xref rid="cit0062" ref-type="bibr">62</xref> There are no data comparing clinical profile or outcomes between subjects who receive their doses within the recommended dosing interval and those who receive a delayed dose.</p></sec></sec><sec id="s0003-s2002-s3003"><title>Adjunctive TM-BUP</title><p>Supplemental TM-BUP was not permitted during the registrational trials<xref rid="cit0006" ref-type="bibr">6</xref> and is not included in the approved USA<xref rid="cit0022" ref-type="bibr">22</xref> or Canadian<xref rid="cit0023" ref-type="bibr">23</xref> labelling for BUP-XR. Administrative data from Ontario suggest this off-label practice is commonly used: 52.0% of patients treated with BUP-XR received supplemental TM-BUP, including 34.9% more than 14 days following their first injection.<xref rid="cit0036" ref-type="bibr">36</xref> Several studies likewise provided supplemental TM-BUP dosing after initiating BUP-XR,<xref rid="cit0035" ref-type="bibr">35</xref>,<xref rid="cit0037" ref-type="bibr">37</xref>,<xref rid="cit0055" ref-type="bibr">55</xref>,<xref rid="cit0059" ref-type="bibr">59</xref>,<xref rid="cit0063" ref-type="bibr">63</xref> typically to control withdrawal or cravings. Dose, duration, and frequency of use is variable&#8212;ranging from 2 to 4 mg daily in the first few months only in more stable populations with low rates of illicit opioid use who are transitioning from long-term treatment with TM-BUP<xref rid="cit0059" ref-type="bibr">59</xref> to higher doses and longer durations in lower threshold or specialty settings.<xref rid="cit0035" ref-type="bibr">35</xref>,<xref rid="cit0037" ref-type="bibr">37</xref>,<xref rid="cit0055" ref-type="bibr">55</xref> In two retrospective studies from programs where patients had high rates of fentanyl use,<xref rid="cit0035" ref-type="bibr">35</xref>,<xref rid="cit0055" ref-type="bibr">55</xref> over half of patients were provided supplemental TM-BUP. In the first, 4&#8211;24 mg supplemental TM-BUP was given to 55% of patients (daily/as needed).<xref rid="cit0035" ref-type="bibr">35</xref> Supplemental dosing was more frequent in patients with &lt;7-day TM-BUP initiation than those with standard &#8805;7-day stabilization (90% vs 30.4%). In a Canadian rapid access clinic, 53.2% of patients (68.1% reported their opioid of choice was fentanyl) required supplemental TM-BUP in the first three months of treatment, though information on dose or use beyond this time frame was not provided.<xref rid="cit0054" ref-type="bibr">54</xref> There are no studies comparing outcomes between participants who receive supplemental TM-BUP and those who do not.</p></sec></sec></sec><sec id="s0004"><title>Discussion</title><p>Fentanyl&#8217;s dominance in the illicit drug supply has increased the urgency for appropriate clinical management of OUD. Due to its potency, individuals who use fentanyl are at high risk of mortality from respiratory depression and overdose.<xref rid="cit0008" ref-type="bibr">8</xref>,<xref rid="cit0009" ref-type="bibr">9</xref> Individual bolus doses have a rapid, intense onset and short half-life,<xref rid="cit0064" ref-type="bibr">64</xref> which contributes to patients using multiple times a day.<xref rid="cit0065" ref-type="bibr">65</xref> In addition to increasing opioid tolerance, frequent fentanyl use is believed to lead to accumulation in adipose tissue.<xref rid="cit0064" ref-type="bibr">64</xref> While the clinical implications of this have not been established, it has been hypothesized to contribute to prolonged positive urine drug screens, as well as more severe or nonlinear withdrawal presentations<xref rid="cit0064" ref-type="bibr">64</xref> and increased risk of PW during buprenorphine initiations.<xref rid="cit0014" ref-type="bibr">14</xref>,<xref rid="cit0066" ref-type="bibr">66</xref> Furthermore, many patients who use fentanyl are clinically unstable and socioeconomically marginalized, preventing them from effectively managing treatment for this disorder.<xref rid="cit0035" ref-type="bibr">35</xref> Current clinical guidelines for OUD outline that when initiating patients with OUD who use fentanyl with buprenorphine, it is important to achieve therapeutic doses as quickly as possible while also mitigating PW risk.<xref rid="cit0020" ref-type="bibr">20</xref> These guidelines indicate that doses must be both achieved and maintained to sufficiently address withdrawal symptoms and cravings, reduce the risk of overdose from subsequent fentanyl use, and support treatment engagement and retention.<xref rid="cit0020" ref-type="bibr">20</xref> For many patients, buprenorphine doses higher than those included in the approved product information may be needed.<xref rid="cit0020" ref-type="bibr">20</xref>,<xref rid="cit0021" ref-type="bibr">21</xref></p><p>Several strategies to optimize BUP-XR initiation and dosing in patients who use fentanyl have been reported, although these practices are outside the approved use of BUP-XR in the USA and Canada and the level of evidence in support is variable. A large randomized controlled study supports the non-inferior efficacy and comparable safety of BUP-XR initiation following a single 4-mg TM-BUP test dose versus the standard initiation protocol<xref rid="cit0014" ref-type="bibr">14</xref> with case reports, and small, open-label, uncontrolled trials provide preliminary data regarding other methods.<xref rid="cit0031" ref-type="bibr">31</xref>,<xref rid="cit0032" ref-type="bibr">32</xref>,<xref rid="cit0034" ref-type="bibr">34</xref>,<xref rid="cit0042" ref-type="bibr">42&#8211;50</xref> The large randomized controlled trial of rapid/test dose initiation<xref rid="cit0015" ref-type="bibr">15</xref> confirmed prior observations that PW is elevated in patients who use fentanyl when compared to non-fentanyl-using populations.<xref rid="cit0016" ref-type="bibr">16</xref> While in this study, there was no difference in rates of PW between rapid and standard initiation, it has been hypothesized that both micro/low-dose and macro/high-dose initiation protocols may reduce the risk of this outcome,<xref rid="cit0067" ref-type="bibr">67</xref> although there are currently no studies available to investigate this. Given that in the randomized controlled trial individuals who experienced PW with rapid/test dose initiation had high rates of continuation on BUP-XR,<xref rid="cit0014" ref-type="bibr">14</xref> further research is needed to understand how appropriate preparation and management of PW may mitigate the impact of this event on treatment retention and other outcomes.</p><p>In addition to modifications in induction protocols, clinical guidelines, consideration documents,<xref rid="cit0020" ref-type="bibr">20</xref>,<xref rid="cit0021" ref-type="bibr">21</xref> and emerging literature<xref rid="cit0068" ref-type="bibr">68</xref>,<xref rid="cit0069" ref-type="bibr">69</xref> suggest that individuals who use fentanyl may require higher buprenorphine maintenance doses to achieve clinical stability. Exposure-response analysis examining the relationship between buprenorphine plasma concentrations and outcomes in the registrational trials for BUP-XR suggests that individuals who inject drugs may require buprenorphine plasma concentrations of 5&#8211;6 ng/mL to maximize abstinence compared to 2&#8211;3 ng/mL for individuals who do not inject.<xref rid="cit0051" ref-type="bibr">51</xref> This corresponds to improved abstinence in those who inject who were randomized to the 300-mg versus 100-mg maintenance dose observed during the phase 3 trial,<xref rid="cit0051" ref-type="bibr">51</xref> though this has yet to be replicated in individuals who use fentanyl, including those using intranasally or via inhalation. A need for higher buprenorphine levels to stabilize patients using fentanyl may explain the rates of 300-mg maintenance dose use in studies from North America. In contrast, use of the 300-mg maintenance dose appears to be lower in studies from countries such as the UK and Australia,<xref rid="cit0070" ref-type="bibr">70&#8211;73</xref> where illicit fentanyl has lower prevalence.</p><p>Other strategies have been described to achieve elevated buprenorphine levels, such as using supplemental TM-BUP,<xref rid="cit0035" ref-type="bibr">35&#8211;37</xref>,<xref rid="cit0055" ref-type="bibr">55</xref>,<xref rid="cit0059" ref-type="bibr">59</xref>,<xref rid="cit0063" ref-type="bibr">63</xref> and accelerating the dosing interval.<xref rid="cit0014" ref-type="bibr">14</xref>,<xref rid="cit0036" ref-type="bibr">36</xref>,<xref rid="cit0052" ref-type="bibr">52</xref> Uncontrolled data on the use of supplemental dosing in individuals who received &lt;7-day TM-BUP stabilization<xref rid="cit0035" ref-type="bibr">35</xref> and acceleration of the second monthly dose in subjects initiated rapidly following a nonfatal overdose<xref rid="cit0041" ref-type="bibr">41</xref> suggest the potential that individuals with lower levels of stability prior to their first BUP-XR injection may benefit from these strategies; however, randomized controlled studies are needed to establish this. Despite this absence of data, several clinical guidelines support the use of supplemental dosing,<xref rid="cit0017" ref-type="bibr">17&#8211;21</xref> with more limited inclusion of recommendations regarding shorter dosing intervals.<xref rid="cit0019" ref-type="bibr">19</xref> This is reflected in the identified publications, with reports of supplemental dosing appearing in high proportion of patients in multiple publications, compared to accelerated dosing, which was noted in a low number of publications and a small subset of patients. This is a rapidly evolving area of practice, however, and emerging data on the safety and efficacy of rapid initiation along with accelerated initial dosing intervals<xref rid="cit0014" ref-type="bibr">14</xref> suggests opportunities for improving retention in patients at high risk due to frequent fentanyl use. These approaches may not be unique to individuals who use fentanyl, as studies from the UK and Australia have likewise reported supplemental dosing<xref rid="cit0070" ref-type="bibr">70</xref>,<xref rid="cit0073" ref-type="bibr">73</xref> and accelerated loading dose intervals;<xref rid="cit0073" ref-type="bibr">73</xref> as such, further research is needed to identify other clinical factors that may predict the need for higher buprenorphine exposure during the initial stages of treatment.</p><p>Limited data also suggest the need for flexibility to adapt to missed doses to avoid treatment discontinuation. Individuals with OUD often experience socioeconomic marginalization, have medical and psychiatric comorbidities, and/or experience relapse of illicit opioid use that contribute to challenges attending medical appointments, all of which may be further exacerbated in individuals who use fentanyl.<xref rid="cit0035" ref-type="bibr">35</xref> Alternately, it may be hypothesized that as patients stabilize on treatment, the long half-life of BUP-XR and delayed withdrawal symptoms from missed doses may lead patients to deprioritize monthly injections.</p><p>Our findings are limited by the narrative, nonsystematic review strategy, which, while allowing for more flexible investigation of a rapidly evolving clinical area (such as through inclusion of preliminary findings from conference abstracts), may have inadvertently excluded discussion of publications that would address the noted research gaps. Importantly, protocols described are largely supported by small, uncontrolled open-label studies and case reports in specialized settings with small samples sizes and limited duration of follow-up, making conclusions regarding their safety and efficacy across clinical practice premature. Furthermore, while we have hypothesized that use of these protocols is due specifically to the needs of individuals who use fentanyl, in many reports, fentanyl use was presumed based on geography and year, and/or no specific comparisons were done between subjects who were positive versus negative for fentanyl use. Given the likely variability between individuals in the level of fentanyl exposure, even within a specific geographical area, further research is needed to confirm the association between fentanyl use and need for novel treatment approaches.</p></sec><sec id="s0005"><title>Conclusion</title><p>Through a narrative review of evidence from peer-reviewed publications and conference abstracts, this article provides an overview of novel initiation and dosing strategies for BUP-XR in patient populations with confirmed or presumed use of fentanyl. Results from a randomized controlled study indicate that initiating BUP-XR following a single TM-BUP dose is noninferior to standard initiation in terms of treatment retention at injection 2, with similar rates of precipitated withdrawal and adverse events, with prescribing information in the USA updated to include this use. Additionally, &#8220;macro/high-dose&#8221; or &#8220;micro/low-dose&#8221; and &#8220;direct dose&#8221; induction approaches have also been reported, although current evidence is limited to small, uncontrolled studies or case reports. Consistent with evidence from studies of TM-BUP, which suggest individuals who use fentanyl may require higher maintenance doses in order to be retained in treatment, administrative and observational data suggests that use of the 300-mg maintenance dose, shortened intervals between doses, and supplemental TM-BUP may be feasible approaches to increase buprenorphine exposure in patients with ongoing symptoms and may improve retention.</p><p>While adoption of these strategies into clinical practice and guidelines is growing, research is still needed to understand how these strategies may best be employed. Other opioid agonist treatment strategies, as well as alternate long-acting buprenorphine formulations, which have their own unique initiation and dosing protocols, were also not discussed. Indeed, innovations in practice for BUP-XR should not be viewed in isolation, rather all OUD treatment approaches, including other medications as well as nonpharmacological approaches, must all adapt to better address the ongoing opioid crisis. As the illicit drug supply continues to increase in potency and complexity and clinical cases are further complicated by stimulant and benzodiazepine co-use, continued research is urgently needed to evaluate the rapid evolution of clinical management of OUD.</p></sec></body><back><ack><title>Acknowledgments</title><p>Writing and editorial support were provided by Claire Daniele, PhD, of SciPubSupport, LLC, and Colleen Walacavage of CW Editing Service, LLC, and funded by Indivior.</p></ack><sec sec-type="COI-statement" id="s0006"><title>Disclosure</title><p>KL: Speaker&#8217;s honorarium: Indivior, Knight, Janssen, Otsuka, Master Clinician Alliance. AM: Speaker&#8217;s honorarium: Indivior, Master Clinician Alliance, Advisory Board: Indivior. BH: Speaker&#8217;s honorarium: Master Clinician Alliance. MD: Employed by Indivior. JK: Employed by Indivior. The authors report no other conflicts of interest in this work.</p></sec><ref-list><title>References</title><ref id="cit0001"><label>1.</label><mixed-citation publication-type="book"><collab>National Institute of Drug Abuse</collab>. <article-title>U.S. Overdose deaths involving any opioid by sex, 1999&#8211;2022</article-title>. <publisher-name>National Center for Health Statistics</publisher-name>; <year>2024</year>. <comment>Available from</comment>: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://nida.nih.gov/research-topics/trends-statistics/overdose-death-rates" ext-link-type="uri">https://nida.nih.gov/research-topics/trends-statistics/overdose-death-rates</ext-link>. <date-in-citation>Accessed <month>September</month><day>23</day>, 2024</date-in-citation>.</mixed-citation></ref><ref id="cit0002"><label>2.</label><mixed-citation publication-type="book"><article-title>Federal, provincial, and territorial special advisory committee on toxic drug poisonings. Opioid- and stimulant-related harms in Canada</article-title>. <publisher-name>Public Health Agency of Canada</publisher-name>; <year>2024</year>. <comment>Available from</comment>: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://health-infobase.canada.ca/substance-related-harms/opioids-stimulants/maps.html" ext-link-type="uri">https://health-infobase.canada.ca/substance-related-harms/opioids-stimulants/maps.html</ext-link>. <date-in-citation>Accessed <month>September</month><day>23</day>, 2024</date-in-citation>.</mixed-citation></ref><ref id="cit0003"><label>3.</label><mixed-citation publication-type="book"><string-name name-style="western"><surname>Holton</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gomes</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Leece</surname><given-names>P</given-names></string-name>, et al. <article-title>Prescribing patterns, substance use disorder diagnoses and access to treatment prior to substance-related toxicity deaths in Ontario</article-title>. <publisher-name>Ontario Drug Policy Research Network</publisher-name>; <year>2024</year>. <comment>Available from</comment>: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://odprn.ca/wp-content/uploads/2024/04/Substance-Toxicity-Report-2-Final.pdf" ext-link-type="uri">https://odprn.ca/wp-content/uploads/2024/04/Substance-Toxicity-Report-2-Final.pdf</ext-link>. <date-in-citation>Accessed <month>October</month><day>23</day>, 2024</date-in-citation>.</mixed-citation></ref><ref id="cit0004"><label>4.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Pearce</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Min</surname><given-names>JE</given-names></string-name>, <string-name name-style="western"><surname>Piske</surname><given-names>M</given-names></string-name>, et al. <article-title>Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study</article-title>. <source><italic toggle="yes">BMJ</italic></source>. <year>2020</year>;<volume>368</volume>:<fpage>m772</fpage>. doi:<pub-id pub-id-type="doi">10.1136/bmj.m772</pub-id><pub-id pub-id-type="pmid">32234712</pub-id><pub-id pub-id-type="pmcid">PMC7190018</pub-id></mixed-citation></ref><ref id="cit0005"><label>5.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Gomes</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>McCormack</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Bozinoff</surname><given-names>N</given-names></string-name>, et al. <article-title>Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population-based propensity-score matched cohort study</article-title>. <source><italic toggle="yes">Addiction</italic></source>. <year>2022</year>;<volume>117</volume>(<issue>7</issue>):<fpage>1972</fpage>&#8211;<lpage>1981</lpage>. doi:<pub-id pub-id-type="doi">10.1111/add.15862</pub-id><pub-id pub-id-type="pmid">35257434</pub-id><pub-id pub-id-type="pmcid">PMC9313829</pub-id></mixed-citation></ref><ref id="cit0006"><label>6.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Haight</surname><given-names>BR</given-names></string-name>, <string-name name-style="western"><surname>Learned</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Laffont</surname><given-names>CM</given-names></string-name>, et al. <article-title>Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial</article-title>. <source><italic toggle="yes">Lancet</italic></source>. <year>2019</year>;<volume>393</volume>(<issue>10173</issue>):<fpage>778</fpage>&#8211;<lpage>790</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(18)32259-1</pub-id><pub-id pub-id-type="pmid">30792007</pub-id></mixed-citation></ref><ref id="cit0007"><label>7.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Laffont</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Ngaimisi</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Gopalakrishnan</surname><given-names>M</given-names></string-name>, et al. <article-title>Buprenorphine exposure levels to optimize treatment outcomes in opioid use disorder</article-title>. <source><italic toggle="yes">Front Pharmacol</italic></source>. <year>2022</year>;<volume>13</volume>:<fpage>1052113</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fphar.2022.1052113</pub-id><pub-id pub-id-type="pmid">36467036</pub-id><pub-id pub-id-type="pmcid">PMC9715596</pub-id></mixed-citation></ref><ref id="cit0008"><label>8.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Moss</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Algera</surname><given-names>MH</given-names></string-name>, <string-name name-style="western"><surname>Dobbins</surname><given-names>R</given-names></string-name>, et al. <article-title>Effect of sustained high buprenorphine plasma concentrations on fentanyl-induced respiratory depression: a placebo-controlled crossover study in healthy volunteers and opioid-tolerant patients</article-title>. <source><italic toggle="yes">PLoS One</italic></source>. <year>2022</year>;<volume>17</volume>(<issue>1</issue>):<fpage>e0256752</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0256752</pub-id><pub-id pub-id-type="pmid">35085249</pub-id><pub-id pub-id-type="pmcid">PMC8794186</pub-id></mixed-citation></ref><ref id="cit0009"><label>9.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Olofsen</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Algera</surname><given-names>MH</given-names></string-name>, <string-name name-style="western"><surname>Moss</surname><given-names>L</given-names></string-name>, et al. <article-title>Modeling buprenorphine reduction of fentanyl-induced respiratory depression</article-title>. <source><italic toggle="yes">JCI Insight</italic></source>. <year>2022</year>;<volume>7</volume>(<issue>9</issue>):<fpage>e156973</fpage>. doi:<pub-id pub-id-type="doi">10.1172/jci.insight.156973</pub-id><pub-id pub-id-type="pmid">35316224</pub-id><pub-id pub-id-type="pmcid">PMC9090248</pub-id></mixed-citation></ref><ref id="cit0010"><label>10.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Lee</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Merali</surname><given-names>T</given-names></string-name>, et al. <article-title>Real-world evidence for impact of opioid agonist therapy on nonfatal overdose in patients with opioid use disorder during the COVID-19 pandemic</article-title>. <source><italic toggle="yes">J Addict Med</italic></source>. <year>2023</year>;<volume>17</volume>(<issue>6</issue>):<fpage>e374</fpage>&#8211;<lpage>e381</lpage>. doi:<pub-id pub-id-type="doi">10.1097/ADM.0000000000001213</pub-id><pub-id pub-id-type="pmid">37934531</pub-id></mixed-citation></ref><ref id="cit0011"><label>11.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Jalal</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Buchanich</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Roberts</surname><given-names>MS</given-names></string-name>, <string-name name-style="western"><surname>Balmert</surname><given-names>LC</given-names></string-name>, <string-name name-style="western"><surname>Zhang</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Burke</surname><given-names>DS</given-names></string-name>. <article-title>Changing dynamics of the drug overdose epidemic in the United States from 1979 through 2016</article-title>. <source><italic toggle="yes">Science</italic></source>. <year>2018</year>;<volume>361</volume>(<issue>6408</issue>):<fpage>eaau1184</fpage>. doi:<pub-id pub-id-type="doi">10.1126/science.aau1184</pub-id><pub-id pub-id-type="pmid">30237320</pub-id><pub-id pub-id-type="pmcid">PMC8025225</pub-id></mixed-citation></ref><ref id="cit0012"><label>12.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Gryczynski</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Nichols</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Schwartz</surname><given-names>RP</given-names></string-name>, <string-name name-style="western"><surname>Mitchell</surname><given-names>SG</given-names></string-name>, <string-name name-style="western"><surname>Hill</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Wireman</surname><given-names>K</given-names></string-name>. <article-title>Fentanyl exposure and preferences among individuals starting treatment for opioid use disorder</article-title>. <source><italic toggle="yes">Drug Alcohol Depend</italic></source>. <year>2019</year>;<volume>204</volume>:<fpage>107515</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2019.06.017</pub-id><pub-id pub-id-type="pmid">31525569</pub-id><pub-id pub-id-type="pmcid">PMC7227777</pub-id></mixed-citation></ref><ref id="cit0013"><label>13.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Varshneya</surname><given-names>NB</given-names></string-name>, <string-name name-style="western"><surname>Thakrar</surname><given-names>AP</given-names></string-name>, <string-name name-style="western"><surname>Hobelmann</surname><given-names>JG</given-names></string-name>, <string-name name-style="western"><surname>Dunn</surname><given-names>KE</given-names></string-name>, <string-name name-style="western"><surname>Huhn</surname><given-names>AS</given-names></string-name>. <article-title>Evidence of buprenorphine-precipitated withdrawal in persons who use fentanyl</article-title>. <source><italic toggle="yes">J Addict Med</italic></source>. <year>2022</year>;<volume>16</volume>(<issue>4</issue>):<fpage>e265</fpage>&#8211;<lpage>e268</lpage>. doi:<pub-id pub-id-type="doi">10.1097/adm.0000000000000922</pub-id><pub-id pub-id-type="pmid">34816821</pub-id><pub-id pub-id-type="pmcid">PMC9124721</pub-id></mixed-citation></ref><ref id="cit0014"><label>14.</label><mixed-citation publication-type="confproc"><string-name name-style="western"><surname>Shiwach</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Le Foll</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Dunn</surname><given-names>K</given-names></string-name>, et al. <article-title>A randomized open-label study comparing rapid and standard inductions to injectable buprenorphine extended-release (BUP-XR) treatment</article-title>. <conf-name>Abstract presented at: College on Problems of Drug Dependence (CPDD) 86th Annual Scientific Meeting</conf-name>; <month>June</month><day>15&#8211;19</day>, <year>2024</year>; <conf-loc>Montreal, Canada</conf-loc>.</mixed-citation></ref><ref id="cit0015"><label>15.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Socias</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Wood</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Le Foll</surname><given-names>B</given-names></string-name>, et al. <article-title>Impact of fentanyl use on initiation and discontinuation of methadone and buprenorphine/naloxone among people with prescription-type opioid use disorder: secondary analysis of a Canadian treatment trial</article-title>. <source><italic toggle="yes">Addiction</italic></source>. <year>2022</year>;<volume>117</volume>(<issue>10</issue>):<fpage>2662</fpage>&#8211;<lpage>2672</lpage>. doi:<pub-id pub-id-type="doi">10.1111/add.15954</pub-id><pub-id pub-id-type="pmid">35712892</pub-id><pub-id pub-id-type="pmcid">PMC9969999</pub-id></mixed-citation></ref><ref id="cit0016"><label>16.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Wakeman</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Chang</surname><given-names>Y</given-names></string-name>, <string-name name-style="western"><surname>Regan</surname><given-names>S</given-names></string-name>, et al. <article-title>Impact of fentanyl use on buprenorphine treatment retention and opioid abstinence</article-title>. <source><italic toggle="yes">J Addict Med</italic></source>. <year>2019</year>;<volume>13</volume>(<issue>4</issue>):<fpage>253</fpage>&#8211;<lpage>257</lpage>. doi:<pub-id pub-id-type="doi">10.1097/ADM.0000000000000486</pub-id><pub-id pub-id-type="pmid">30550392</pub-id></mixed-citation></ref><ref id="cit0017"><label>17.</label><mixed-citation publication-type="book"><collab>&#201;quipe de soutien clinique et organisationnel en d&#233;pendance et itin&#233;rance (ESCODI) at the Centre int&#233;gr&#233; universitaire de sant&#233; et de services sociaux, Centre-Sud-de-l&#8217;&#206;le-de-Montr&#233;al (CCSMTL)</collab>. <article-title>A guide to using extended-release buprenorphine (Sublocade<sup>&#174;</sup>) in Opioid Agonist Therapy (OAT)</article-title>. <publisher-name>CCSMTL</publisher-name>; <year>2023</year>. <comment>Available from</comment>: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://dependanceitinerance.ca/wp-content/uploads/2023/06/230612-Outil-Sublocade-EN.pdf" ext-link-type="uri">https://dependanceitinerance.ca/wp-content/uploads/2023/06/230612-Outil-Sublocade-EN.pdf</ext-link>. <date-in-citation>Accessed <month>July</month><day>31</day>, 2023</date-in-citation>.</mixed-citation></ref><ref id="cit0018"><label>18.</label><mixed-citation publication-type="book"><article-title>Initiation of Buprenorphine Extended-Release (BUP-XR) Injection</article-title>. <publisher-name>META:PHI, Ontario Ministry of Health</publisher-name>. <comment>Available from</comment>: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.metaphi.ca/wp-content/uploads/DepotBuprenorphineInitiation.pdf" ext-link-type="uri">https://www.metaphi.ca/wp-content/uploads/DepotBuprenorphineInitiation.pdf</ext-link>. <date-in-citation>Accessed <month>July</month><day>20</day>, 2023</date-in-citation>.</mixed-citation></ref><ref id="cit0019"><label>19.</label><mixed-citation publication-type="book"><article-title>A guide to the use of depot buprenorphine</article-title>. <publisher-name>META:PHI, Ontario Ministry of Health</publisher-name>. <comment>Available from</comment>: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.metaphi.ca/wp-content/uploads/Guide_DepotBuprenorphine.pdf" ext-link-type="uri">https://www.metaphi.ca/wp-content/uploads/Guide_DepotBuprenorphine.pdf</ext-link>. <date-in-citation>Accessed <month>July</month><day>20</day>, 2023</date-in-citation>.</mixed-citation></ref><ref id="cit0020"><label>20.</label><mixed-citation publication-type="book"><article-title>A guideline for the clinical management of opioid use disorder</article-title>. <publisher-name>British Columbia Centre on Substance Use, BC Ministry of Health, and BC Ministry of Mental Health and Addictions</publisher-name>. <comment>[updated November, 2023]</comment>. <comment>Available from</comment>: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.bccsu.ca/opioid-use-disorder" ext-link-type="uri">https://www.bccsu.ca/opioid-use-disorder</ext-link>. <date-in-citation>Accessed <month>October</month><day>23</day>, 2024</date-in-citation>.</mixed-citation></ref><ref id="cit0021"><label>21.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Weimer</surname><given-names>MB</given-names></string-name>, <string-name name-style="western"><surname>Herring</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Kawasaki</surname><given-names>SS</given-names></string-name>, <string-name name-style="western"><surname>Meyer</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kleykamp</surname><given-names>BA</given-names></string-name>, <string-name name-style="western"><surname>Ramsey</surname><given-names>KS</given-names></string-name>. <article-title>ASAM clinical considerations: buprenorphine treatment of opioid use disorder for individuals using high-potency synthetic opioids</article-title>. <source><italic toggle="yes">J Addict Med</italic></source>. <year>2023</year>;<volume>17</volume>(<issue>6</issue>):<fpage>632</fpage>&#8211;<lpage>639</lpage>. doi:<pub-id pub-id-type="doi">10.1097/ADM.0000000000001202</pub-id><pub-id pub-id-type="pmid">37934520</pub-id></mixed-citation></ref><ref id="cit0022"><label>22.</label><mixed-citation publication-type="book"><article-title>Sublocade (extended-release buprenorphine injection) [package insert]</article-title>. <publisher-loc>Richmond, VA</publisher-loc>: <publisher-name>Indivior</publisher-name>; <year>2023</year>.</mixed-citation></ref><ref id="cit0023"><label>23.</label><mixed-citation publication-type="book"><article-title>Sublocade (extended-release buprenorphine injection) [product monograph]</article-title>. <publisher-loc>Hull, UK</publisher-loc>: <publisher-name>Indivior UK Ltd.</publisher-name>; <year>2022</year>.</mixed-citation></ref><ref id="cit0024"><label>24.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>O&#8217;Donnell</surname><given-names>JK</given-names></string-name>, <string-name name-style="western"><surname>Gladden</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Seth</surname><given-names>P</given-names></string-name>. <article-title>Trends in deaths involving heroin and synthetic opioids excluding methadone, and law enforcement drug product reports, by census region - United States, 2006&#8211;2015</article-title>. <source><italic toggle="yes">MMWR Morb Mortal Wkly Rep</italic></source>. <year>2017</year>;<volume>66</volume>(<issue>34</issue>):<fpage>897</fpage>&#8211;<lpage>903</lpage>. doi:<pub-id pub-id-type="doi">10.15585/mmwr.mm6634a2</pub-id><pub-id pub-id-type="pmid">28859052</pub-id><pub-id pub-id-type="pmcid">PMC5657786</pub-id></mixed-citation></ref><ref id="cit0025"><label>25.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Wilson</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Kariisa</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Seth</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Smith</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Davis</surname><given-names>NL</given-names></string-name>. <article-title>Drug and opioid-involved overdose deaths - United States, 2017&#8211;2018</article-title>. <source><italic toggle="yes">MMWR Morb Mortal Wkly Rep</italic></source>. <year>2020</year>;<volume>69</volume>(<issue>11</issue>):<fpage>290</fpage>&#8211;<lpage>297</lpage>. doi:<pub-id pub-id-type="doi">10.15585/mmwr.mm6911a4</pub-id><pub-id pub-id-type="pmid">32191688</pub-id><pub-id pub-id-type="pmcid">PMC7739981</pub-id></mixed-citation></ref><ref id="cit0026"><label>26.</label><mixed-citation publication-type="book"><article-title>Drug analysis service: trends 2012&#8211;2019</article-title>. <publisher-name>Health Canada, Public Health Agency of Canada</publisher-name>; <year>2019</year>. <comment>Available from</comment>: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.canada.ca/en/health-canada/services/health-concerns/controlled-substances-precursor-chemicals/drug-analysis-service/2019-drug-analysis-service-trends.html#a3" ext-link-type="uri">https://www.canada.ca/en/health-canada/services/health-concerns/controlled-substances-precursor-chemicals/drug-analysis-service/2019-drug-analysis-service-trends.html#a3</ext-link>. <date-in-citation>Accessed <month>September</month>, 2023</date-in-citation>.</mixed-citation></ref><ref id="cit0027"><label>27.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Lam</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Barratt</surname><given-names>MJ</given-names></string-name>, <string-name name-style="western"><surname>Bartlett</surname><given-names>M</given-names></string-name>, et al. <article-title>Infrequent detection of unintentional fentanyl use via urinalysis among people who regularly inject opioids in Sydney and Melbourne, Australia</article-title>. <source><italic toggle="yes">Addiction</italic></source>. <year>2022</year>;<volume>117</volume>(<issue>8</issue>):<fpage>2331</fpage>&#8211;<lpage>2337</lpage>. doi:<pub-id pub-id-type="doi">10.1111/add.15832</pub-id><pub-id pub-id-type="pmid">35129225</pub-id><pub-id pub-id-type="pmcid">PMC9544654</pub-id></mixed-citation></ref><ref id="cit0028"><label>28.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Pierce</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>van Amsterdam</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kalkman</surname><given-names>GA</given-names></string-name>, <string-name name-style="western"><surname>Schellekens</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>van den Brink</surname><given-names>W</given-names></string-name>. <article-title>Is Europe facing an opioid crisis like the United States? An analysis of opioid use and related adverse effects in 19 European countries between 2010 and 2018</article-title>. <source><italic toggle="yes">Eur Psychiatry</italic></source>. <year>2021</year>;<volume>64</volume>(<issue>1</issue>):<fpage>e47</fpage>. doi:<pub-id pub-id-type="doi">10.1192/j.eurpsy.2021.2219</pub-id><pub-id pub-id-type="pmid">34165059</pub-id><pub-id pub-id-type="pmcid">PMC8316471</pub-id></mixed-citation></ref><ref id="cit0029"><label>29.</label><mixed-citation publication-type="book"><article-title>Suboxone (buprenorphine/naloxone sublingual tablets and soluble film) [product monograph]</article-title>. <publisher-loc>Hull, UK</publisher-loc>. <publisher-name>Indivior UK Ltd.</publisher-name>; <year>2023</year>.</mixed-citation></ref><ref id="cit0030"><label>30.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Sue</surname><given-names>KL</given-names></string-name>, <string-name name-style="western"><surname>Cohen</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Tilley</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Yocheved</surname><given-names>A</given-names></string-name>. <article-title>A plea from people who use drugs to clinicians: new ways to initiate buprenorphine are urgently needed in the fentanyl era</article-title>. <source><italic toggle="yes">J Addict Med</italic></source>. <year>2022</year>;<volume>16</volume>(<issue>4</issue>):<fpage>389</fpage>&#8211;<lpage>391</lpage>. doi:<pub-id pub-id-type="doi">10.1097/ADM.0000000000000952</pub-id><pub-id pub-id-type="pmid">35020693</pub-id></mixed-citation></ref><ref id="cit0031"><label>31.</label><mixed-citation publication-type="confproc"><string-name name-style="western"><surname>Wethern</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Calcaterra</surname><given-names>SL</given-names></string-name>, <string-name name-style="western"><surname>Klie</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Thurstone</surname><given-names>C</given-names></string-name>. <article-title>Immediate fentanyl to extended-release buprenorphine transition in two adolescents with OUD</article-title>. <conf-name>Poster presented at: American Society of Addiction Medicine Annual Conference</conf-name>; <month>April</month><day>13&#8211;16</day>, <year>2023</year>; <conf-loc>Washington, DC</conf-loc>.</mixed-citation></ref><ref id="cit0032"><label>32.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Taylor</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Gott</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Weisenthal</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Colicchio</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Dyer</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Komaromy</surname><given-names>MS</given-names></string-name>. <article-title>Post-overdose extended-release buprenorphine initiation facilitated by a partnership between emergency medical services and an outpatient substance use disorder observation unit</article-title>. <source><italic toggle="yes">Subst Use Addctn J</italic></source>. <year>2024</year>;<volume>45</volume>(<issue>4</issue>):<fpage>771</fpage>&#8211;<lpage>776</lpage>. doi:<pub-id pub-id-type="doi">10.1177/29767342241249386</pub-id><pub-id pub-id-type="pmid">38736211</pub-id></mixed-citation></ref><ref id="cit0033"><label>33.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Hansen</surname><given-names>ER</given-names></string-name>, <string-name name-style="western"><surname>South</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Lofwall</surname><given-names>MR</given-names></string-name>, <string-name name-style="western"><surname>Fanucchi</surname><given-names>LC</given-names></string-name>. <article-title>Extended-release buprenorphine administered at discharge in hospitalized persons with opioid use disorder: a case series</article-title>. <source><italic toggle="yes">J Addict Med</italic></source>. <year>2024</year>;<volume>18</volume>(<issue>1</issue>):<fpage>65</fpage>&#8211;<lpage>67</lpage>. doi:<pub-id pub-id-type="doi">10.1097/ADM.0000000000001239</pub-id><pub-id pub-id-type="pmid">37874645</pub-id></mixed-citation></ref><ref id="cit0034"><label>34.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Kahan</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Marion-Bellemare</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Samson</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Srivastava</surname><given-names>A</given-names></string-name>. <article-title>&#8220;Macrodosing&#8221; sublingual buprenorphine and extended-release buprenorphine in a hospital setting: 2 case reports</article-title>. <source><italic toggle="yes">J Addict Med</italic></source>. <year>2023</year>;<volume>17</volume>(<issue>4</issue>):<fpage>485</fpage>&#8211;<lpage>487</lpage>. doi:<pub-id pub-id-type="doi">10.1097/ADM.0000000000001148</pub-id><pub-id pub-id-type="pmid">37579117</pub-id></mixed-citation></ref><ref id="cit0035"><label>35.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Peckham</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Kehoe</surname><given-names>LG</given-names></string-name>, <string-name name-style="western"><surname>Gray</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Wakeman</surname><given-names>SE</given-names></string-name>. <article-title>Real-world outcomes with extended-release buprenorphine (XR-BUP) in a low threshold bridge clinic: a retrospective case series</article-title>. <source><italic toggle="yes">J Subst Abuse Treat</italic></source>. <year>2021</year>;<volume>126</volume>:<fpage>108316</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jsat.2021.108316</pub-id><pub-id pub-id-type="pmid">34116808</pub-id></mixed-citation></ref><ref id="cit0036"><label>36.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Iacono</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Wang</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Tadrous</surname><given-names>M</given-names></string-name>, et al. <article-title>Characteristics, treatment patterns and retention with extended-release subcutaneous buprenorphine for opioid use disorder: a population-based cohort study in Ontario, Canada</article-title>. <source><italic toggle="yes">Drug Alcohol Depend</italic></source>. <year>2024</year>;<volume>254</volume>:<fpage>111032</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2023.111032</pub-id><pub-id pub-id-type="pmid">38043224</pub-id></mixed-citation></ref><ref id="cit0037"><label>37.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Heil</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Salzman</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Hunter</surname><given-names>K</given-names></string-name>, et al. <article-title>Evaluation of an injectable monthly extended-release buprenorphine program in a low-barrier specialty addiction medicine clinic</article-title>. <source><italic toggle="yes">J Subst Use Addict Treat</italic></source>. <year>2024</year>;<volume>156</volume>:<fpage>209183</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.josat.2023.209183</pub-id><pub-id pub-id-type="pmid">37879433</pub-id></mixed-citation></ref><ref id="cit0038"><label>38.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>O&#8217;Connor</surname><given-names>AB</given-names></string-name>, <string-name name-style="western"><surname>Gelsinger</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Donovan</surname><given-names>SM</given-names></string-name>, <string-name name-style="western"><surname>Marshall</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Ahrens</surname><given-names>KA</given-names></string-name>. <article-title>Community buprenorphine continuation post-release following extended release vs. sublingual buprenorphine during incarceration: a pilot project in Maine</article-title>. <source><italic toggle="yes">Health Justice</italic></source>. <year>2024</year>;<volume>12</volume>(<issue>1</issue>):<fpage>28</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s40352-024-00281-w</pub-id><pub-id pub-id-type="pmid">38940853</pub-id><pub-id pub-id-type="pmcid">PMC11212228</pub-id></mixed-citation></ref><ref id="cit0039"><label>39.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Hassman</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Strafford</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Shinde</surname><given-names>SN</given-names></string-name>, <string-name name-style="western"><surname>Heath</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Boyett</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Dobbins</surname><given-names>RL</given-names></string-name>. <article-title>Open-label, rapid initiation pilot study for extended-release buprenorphine subcutaneous injection</article-title>. <source><italic toggle="yes">Am J Drug Alcohol Abuse</italic></source>. <year>2023</year>;<volume>49</volume>(<issue>1</issue>):<fpage>43</fpage>&#8211;<lpage>52</lpage>. doi:<pub-id pub-id-type="doi">10.1080/00952990.2022.2106574</pub-id><pub-id pub-id-type="pmid">36001871</pub-id></mixed-citation></ref><ref id="cit0040"><label>40.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Mariani</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Dobbins</surname><given-names>RL</given-names></string-name>, <string-name name-style="western"><surname>Heath</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Gray</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Hassman</surname><given-names>H</given-names></string-name>. <article-title>Open-label investigation of rapid initiation of extended-release buprenorphine in patients using fentanyl and fentanyl analogs</article-title>. <source><italic toggle="yes">Am J Addict</italic></source>. <year>2023</year>;<fpage>1</fpage>&#8211;<lpage>7</lpage>. doi:<pub-id pub-id-type="doi">10.1111/ajad.13484</pub-id><pub-id pub-id-type="pmid">37936553</pub-id></mixed-citation></ref><ref id="cit0041"><label>41.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Ochalek</surname><given-names>TA</given-names></string-name>, <string-name name-style="western"><surname>Ringwood</surname><given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Davis</surname><given-names>TT</given-names></string-name>, et al. <article-title>Rapid induction onto extended-release injectable buprenorphine following opioid overdose: a case series</article-title>. <source><italic toggle="yes">Drug Alcohol Depend Rep</italic></source>. <year>2023</year>;<volume>7</volume>:<fpage>100144</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.dadr.2023.100144</pub-id><pub-id pub-id-type="pmid">37033158</pub-id><pub-id pub-id-type="pmcid">PMC10073633</pub-id></mixed-citation></ref><ref id="cit0042"><label>42.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Mariani</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Mahony</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Iqbal</surname><given-names>MN</given-names></string-name>, et al. <article-title>Case series: rapid induction onto long acting buprenorphine injection for high potency synthetic opioid users</article-title>. <source><italic toggle="yes">Am J Addict</italic></source>. <year>2020</year>;<volume>29</volume>(<issue>4</issue>):<fpage>345</fpage>&#8211;<lpage>348</lpage>. doi:<pub-id pub-id-type="doi">10.1111/ajad.13018</pub-id><pub-id pub-id-type="pmid">32167629</pub-id><pub-id pub-id-type="pmcid">PMC7383940</pub-id></mixed-citation></ref><ref id="cit0043"><label>43.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Mariani</surname><given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Mahony</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Podell</surname><given-names>SC</given-names></string-name>, et al. <article-title>Open-label trial of a single-day induction onto buprenorphine extended-release injection for users of heroin and fentanyl</article-title>. <source><italic toggle="yes">Am J Addict</italic></source>. <year>2021</year>;<volume>30</volume>(<issue>5</issue>):<fpage>470</fpage>&#8211;<lpage>476</lpage>. doi:<pub-id pub-id-type="doi">10.1111/ajad.13193</pub-id><pub-id pub-id-type="pmid">34223681</pub-id><pub-id pub-id-type="pmcid">PMC8459386</pub-id></mixed-citation></ref><ref id="cit0044"><label>44.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>LeSaint</surname><given-names>KT</given-names></string-name>, <string-name name-style="western"><surname>Kendric</surname><given-names>KJ</given-names></string-name>, <string-name name-style="western"><surname>Logan</surname><given-names>AA</given-names></string-name>. <article-title>Successful administration of extended-release buprenorphine in the emergency department</article-title>. <source><italic toggle="yes">Am J Emerg Med</italic></source>. <year>2024</year>;<volume>84</volume>:<fpage>189.e1</fpage>&#8211;<lpage>189.e3</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ajem.2024.07.046</pub-id><pub-id pub-id-type="pmid">39089938</pub-id></mixed-citation></ref><ref id="cit0045"><label>45.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Hailozian</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Luftig</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Liang</surname><given-names>A</given-names></string-name>, et al. <article-title>Synergistic effect of ketamine and buprenorphine observed in the treatment of buprenorphine precipitated opioid withdrawal in a patient with fentanyl use</article-title>. <source><italic toggle="yes">J Addict Med</italic></source>. <year>2022</year>;<volume>16</volume>(<issue>4</issue>):<fpage>483</fpage>&#8211;<lpage>487</lpage>. doi:<pub-id pub-id-type="doi">10.1097/ADM.0000000000000929</pub-id><pub-id pub-id-type="pmid">34789683</pub-id></mixed-citation></ref><ref id="cit0046"><label>46.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Azar</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Wong</surname><given-names>JSH</given-names></string-name>, <string-name name-style="western"><surname>Jassemi</surname><given-names>S</given-names></string-name>, et al. <article-title>A case report: rapid micro-induction of buprenorphine/naloxone to administer buprenorphine extended-release in an adolescent with severe opioid use disorder</article-title>. <source><italic toggle="yes">Am J Addict</italic></source>. <year>2020</year>;<volume>29</volume>(<issue>6</issue>):<fpage>531</fpage>&#8211;<lpage>535</lpage>. doi:<pub-id pub-id-type="doi">10.1111/ajad.13050</pub-id><pub-id pub-id-type="pmid">32346944</pub-id></mixed-citation></ref><ref id="cit0047"><label>47.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Azar</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Wong</surname><given-names>JSH</given-names></string-name>, <string-name name-style="western"><surname>Mathew</surname><given-names>N</given-names></string-name>, et al. <article-title>48-hour induction of transdermal buprenorphine to extended-release buprenorphine</article-title>. <source><italic toggle="yes">J Addict Med</italic></source>. <year>2024</year>;<volume>18</volume>(<issue>1</issue>):<fpage>82</fpage>&#8211;<lpage>85</lpage>. doi:<pub-id pub-id-type="doi">10.1097/ADM.0000000000001231</pub-id><pub-id pub-id-type="pmid">37847573</pub-id></mixed-citation></ref><ref id="cit0048"><label>48.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Azar</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Schneiderman</surname><given-names>H</given-names></string-name>, <string-name name-style="western"><surname>Barron</surname><given-names>H</given-names></string-name>, et al. <article-title>Rapid induction of transdermal buprenorphine to subcutaneous extended-release buprenorphine for the treatment of opioid use disorder</article-title>. <source><italic toggle="yes">Addict Sci Clin Pract</italic></source>. <year>2024</year>;<volume>19</volume>(<issue>1</issue>):<fpage>50</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s13722-024-00479-1</pub-id><pub-id pub-id-type="pmid">38886826</pub-id><pub-id pub-id-type="pmcid">PMC11184727</pub-id></mixed-citation></ref><ref id="cit0049"><label>49.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Gorham</surname><given-names>JW</given-names></string-name>, <string-name name-style="western"><surname>Ansari</surname><given-names>F</given-names></string-name>, <string-name name-style="western"><surname>Sethi</surname><given-names>R</given-names></string-name>. <article-title>The effectiveness of buprenorphine transdermal patch and low dose sublingual buprenorphine induction to transition to long-acting subcutaneous buprenorphine injection in opioid use disorder in inpatient setting</article-title>. <source><italic toggle="yes">Kans J Med</italic></source>. <year>2024</year>;<volume>17</volume>:<fpage>20</fpage>&#8211;<lpage>21</lpage>. doi:<pub-id pub-id-type="doi">10.17161/kjm.vol17.21229</pub-id><pub-id pub-id-type="pmid">38694173</pub-id><pub-id pub-id-type="pmcid">PMC11060775</pub-id></mixed-citation></ref><ref id="cit0050"><label>50.</label><mixed-citation publication-type="confproc"><string-name name-style="western"><surname>Mooney</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Bucheit</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Rowell</surname><given-names>M</given-names></string-name>, et al. <article-title>Extended-release injectable buprenorphine for same- day induction&#8212;a case series</article-title>. <conf-name>Poster presented at: American Society of Addiction Medicine 55th Annual Conference</conf-name>; <month>April</month><day>4&#8211;7</day>, <year>2024</year>; <conf-loc>Grapevine, TX</conf-loc>.</mixed-citation></ref><ref id="cit0051"><label>51.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Greenwald</surname><given-names>MK</given-names></string-name>, <string-name name-style="western"><surname>Wiest</surname><given-names>KL</given-names></string-name>, <string-name name-style="western"><surname>Haight</surname><given-names>BR</given-names></string-name>, <string-name name-style="western"><surname>Laffont</surname><given-names>CM</given-names></string-name>, <string-name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></string-name>. <article-title>Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder</article-title>. <source><italic toggle="yes">Harm Reduct J</italic></source>. <year>2023</year>;<volume>20</volume>(<issue>1</issue>):<fpage>173</fpage>. doi:<pub-id pub-id-type="doi">10.1186/s12954-023-00906-7</pub-id><pub-id pub-id-type="pmid">38042801</pub-id><pub-id pub-id-type="pmcid">PMC10693082</pub-id></mixed-citation></ref><ref id="cit0052"><label>52.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Morgan</surname><given-names>JR</given-names></string-name>, <string-name name-style="western"><surname>Walley</surname><given-names>AY</given-names></string-name>, <string-name name-style="western"><surname>Murphy</surname><given-names>SM</given-names></string-name>, et al. <article-title>Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort</article-title>. <source><italic toggle="yes">Drug Alcohol Depend</italic></source>. <year>2021</year>;<volume>225</volume>:<fpage>108764</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2021.108764</pub-id><pub-id pub-id-type="pmid">34051547</pub-id><pub-id pub-id-type="pmcid">PMC8488795</pub-id></mixed-citation></ref><ref id="cit0053"><label>53.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Griffith</surname><given-names>PS</given-names></string-name>, <string-name name-style="western"><surname>Brown</surname><given-names>LM</given-names></string-name>, <string-name name-style="western"><surname>Lensing</surname><given-names>SY</given-names></string-name>, et al. <article-title>Opioid use disorder: treatment outcomes in U.S. Veterans</article-title>. <source><italic toggle="yes">J Addict Nurs</italic></source>. <year>2022</year>;<volume>33</volume>(<issue>4</issue>):<fpage>322</fpage>&#8211;<lpage>325</lpage>. doi:<pub-id pub-id-type="doi">10.1097/JAN.0000000000000499</pub-id><pub-id pub-id-type="pmid">37140420</pub-id></mixed-citation></ref><ref id="cit0054"><label>54.</label><mixed-citation publication-type="confproc"><string-name name-style="western"><surname>Lee</surname><given-names>K</given-names></string-name>. <article-title>Treatment retention with monthly buprenorphine extended release injection: results from a Canadian Rapid Access Addiction Medicine Clinic: 21 month data</article-title>. <conf-name>Poster presented virtually at: CSAM-SCMA 2021 Scientific Congress</conf-name>; <month>October</month><day>21&#8211;23</day>, <year>2021</year>; <conf-loc>Ottawa, Canada</conf-loc>.</mixed-citation></ref><ref id="cit0055"><label>55.</label><mixed-citation publication-type="confproc"><string-name name-style="western"><surname>Deng</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Hann</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Bach</surname><given-names>P</given-names></string-name>. <article-title>Comparison of 100mg vs 300mg buprenorphine extended-release injection in maintenance treatment of opioid use disorder at a low barrier outpatient clinic</article-title>. <conf-name>Poster presented at: CSAM-SMCA 2023 Scientific Conference</conf-name>; <month>October</month><day>19&#8211;21</day>, <year>2023</year>; <conf-loc>Victoria, British Columbia</conf-loc>.</mixed-citation></ref><ref id="cit0056"><label>56.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Galati</surname><given-names>BM</given-names></string-name>, <string-name name-style="western"><surname>Wenzinger</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Rogers</surname><given-names>CE</given-names></string-name>, <string-name name-style="western"><surname>Cooke</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Kelly</surname><given-names>JC</given-names></string-name>. <article-title>Buprenorphine extended-release treatment for opioid use disorder in the postpartum period</article-title>. <source><italic toggle="yes">Obstet Gynecol</italic></source>. <year>2023</year>;<volume>142</volume>(<issue>5</issue>):<fpage>1148</fpage>&#8211;<lpage>1152</lpage>. doi:<pub-id pub-id-type="doi">10.1097/AOG.0000000000005319</pub-id><pub-id pub-id-type="pmid">37856853</pub-id></mixed-citation></ref><ref id="cit0057"><label>57.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Cotton</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Lo</surname><given-names>K</given-names></string-name>, <string-name name-style="western"><surname>Kurtz</surname><given-names>FB</given-names></string-name>, <string-name name-style="western"><surname>Waldbauer</surname><given-names>L</given-names></string-name>. <article-title>Extended-release buprenorphine outcomes among treatment resistant veterans</article-title>. <source><italic toggle="yes">Am J Drug Alcohol Abuse</italic></source>. <year>2022</year>;<volume>48</volume>(<issue>3</issue>):<fpage>334</fpage>&#8211;<lpage>337</lpage>. doi:<pub-id pub-id-type="doi">10.1080/00952990.2021.1992773</pub-id><pub-id pub-id-type="pmid">34780319</pub-id></mixed-citation></ref><ref id="cit0058"><label>58.</label><mixed-citation publication-type="confproc"><string-name name-style="western"><surname>Hanley</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Farmerie</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Russell</surname><given-names>E</given-names></string-name>, et al. <article-title>A grand milestone: reflections and findings following 1000+ administrations of XR SC Buprenorphine in the outpatient clinic setting</article-title>. <conf-name>Association for Multidisciplinary Education and Research in Substance Use and Addiction 47th Annual National Conference</conf-name>; <month>November</month><day>2&#8211;4</day>, <year>2023</year>; <conf-loc>Washington, DC</conf-loc>.</mixed-citation></ref><ref id="cit0059"><label>59.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Stein</surname><given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>VanNoppen</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Herman</surname><given-names>DS</given-names></string-name>, <string-name name-style="western"><surname>Anderson</surname><given-names>BJ</given-names></string-name>, <string-name name-style="western"><surname>Conti</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bailey</surname><given-names>GL</given-names></string-name>. <article-title>Retention in care for persons with opioid use disorder transitioning from sublingual to injectable buprenorphine</article-title>. <source><italic toggle="yes">J Subst Abuse Treat</italic></source>. <year>2022</year>;<volume>136</volume>:<fpage>108661</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jsat.2021.108661</pub-id><pub-id pub-id-type="pmid">34801283</pub-id></mixed-citation></ref><ref id="cit0060"><label>60.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Martin</surname><given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Berk</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Rich</surname><given-names>JD</given-names></string-name>, <string-name name-style="western"><surname>Kang</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Fritsche</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Clarke</surname><given-names>JG</given-names></string-name>. <article-title>Use of long-acting injectable buprenorphine in the correctional setting</article-title>. <source><italic toggle="yes">J Subst Abuse Treat</italic></source>. <year>2022</year>;<volume>142</volume>:<fpage>108851</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jsat.2022.10885</pub-id><pub-id pub-id-type="pmid">35939914</pub-id><pub-id pub-id-type="pmcid">PMC9743485</pub-id></mixed-citation></ref><ref id="cit0061"><label>61.</label><mixed-citation publication-type="webpage"><article-title>A randomised, double-blind study comparing 2 maintenance dosing regimens of buprenorphine extended-release subcutaneous injection (RBP-6000) in treatment-seeking adult participants with opioid use disorder and high-risk opioid use</article-title>. <source>ClinicalTrials.gov: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04995029">NCT04995029</ext-link></source>. <comment>[updated January 7, 2024]</comment>. <comment>Available from</comment>: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/study/NCT04995029" ext-link-type="uri">https://clinicaltrials.gov/study/NCT04995029</ext-link>. <date-in-citation>Accessed <month>July</month><day>27</day>, 2023</date-in-citation>.</mixed-citation></ref><ref id="cit0062"><label>62.</label><mixed-citation publication-type="confproc"><string-name name-style="western"><surname>Krueger</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Maul</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Tapley</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Lund</surname><given-names>B</given-names></string-name>. <article-title>XR-BUP in the CDOC: lessons learned from &gt;500 injections</article-title>. <conf-name>Poster presented at: American Society of Addiction Medicine Annual Conference</conf-name>; <month>April</month><day>13&#8211;16</day>, <year>2023</year>; <conf-loc>Washington, DC</conf-loc>.</mixed-citation></ref><ref id="cit0063"><label>63.</label><mixed-citation publication-type="confproc"><string-name name-style="western"><surname>ZoBell</surname><given-names>JS</given-names></string-name>, <string-name name-style="western"><surname>Ghauri</surname><given-names>I</given-names></string-name>. <article-title>Transitioning from methadone to extended-release buprenorphine (a case series presentation)</article-title>. <conf-name>Abstract presented at: CSAM-SCMA 2022 Scientific Congress</conf-name>; <month>November</month><day>3&#8211;5</day>, <year>2022</year>; <conf-loc>Saskatoon, Saskatchewan</conf-loc>.</mixed-citation></ref><ref id="cit0064"><label>64.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Bird</surname><given-names>HE</given-names></string-name>, <string-name name-style="western"><surname>Huhn</surname><given-names>AS</given-names></string-name>, <string-name name-style="western"><surname>Dunn</surname><given-names>KE</given-names></string-name>. <article-title>Fentanyl absorption, distribution, metabolism, and excretion: narrative review and clinical significance related to illicitly manufactured fentanyl</article-title>. <source><italic toggle="yes">J Addict Med</italic></source>. <year>2023</year>;<volume>17</volume>(<issue>5</issue>):<fpage>503</fpage>&#8211;<lpage>508</lpage>. doi:<pub-id pub-id-type="doi">10.1097/ADM.0000000000001185</pub-id><pub-id pub-id-type="pmid">37788600</pub-id><pub-id pub-id-type="pmcid">PMC10593981</pub-id></mixed-citation></ref><ref id="cit0065"><label>65.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Mayer</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Boyd</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Collins</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Kennedy</surname><given-names>MC</given-names></string-name>, <string-name name-style="western"><surname>Fairbairn</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>McNeil</surname><given-names>R</given-names></string-name>. <article-title>Characterizing fentanyl-related overdoses and implications for overdose response: findings from a rapid ethnographic study in Vancouver, Canada</article-title>. <source><italic toggle="yes">Drug Alcohol Depend</italic></source>. <year>2018</year>;<volume>193</volume>:<fpage>69</fpage>&#8211;<lpage>74</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.drugalcdep.2018.09.006</pub-id><pub-id pub-id-type="pmid">30343236</pub-id><pub-id pub-id-type="pmcid">PMC6447427</pub-id></mixed-citation></ref><ref id="cit0066"><label>66.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Shearer</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Young</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Fairbairn</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Brar</surname><given-names>R</given-names></string-name>. <article-title>Challenges with buprenorphine inductions in the context of the fentanyl overdose crisis: a case series</article-title>. <source><italic toggle="yes">Drug Alcohol Rev</italic></source>. <year>2022</year>;<volume>41</volume>(<issue>2</issue>):<fpage>444</fpage>&#8211;<lpage>448</lpage>. doi:<pub-id pub-id-type="doi">10.1111/dar.13394</pub-id><pub-id pub-id-type="pmid">34647379</pub-id><pub-id pub-id-type="pmcid">PMC8926080</pub-id></mixed-citation></ref><ref id="cit0067"><label>67.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Greenwald</surname><given-names>MK</given-names></string-name>, <string-name name-style="western"><surname>Herring</surname><given-names>AA</given-names></string-name>, <string-name name-style="western"><surname>Perrone</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Nelson</surname><given-names>LS</given-names></string-name>, <string-name name-style="western"><surname>Azar</surname><given-names>P</given-names></string-name>. <article-title>A neuropharmacological model to explain buprenorphine induction challenges</article-title>. <source><italic toggle="yes">Ann Emerg Med</italic></source>. <year>2022</year>;<volume>80</volume>(<issue>6</issue>):<fpage>509</fpage>&#8211;<lpage>524</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.annemergmed.2022.05.032</pub-id><pub-id pub-id-type="pmid">35940992</pub-id></mixed-citation></ref><ref id="cit0068"><label>68.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Grande</surname><given-names>LA</given-names></string-name>, <string-name name-style="western"><surname>Cundiff</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Greenwald</surname><given-names>MK</given-names></string-name>, <string-name name-style="western"><surname>Murray</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Wright</surname><given-names>TE</given-names></string-name>, <string-name name-style="western"><surname>Martin</surname><given-names>SA</given-names></string-name>. <article-title>Evidence on buprenorphine dose limits: a review</article-title>. <source><italic toggle="yes">J Addict Med</italic></source>. <year>2023</year>;<volume>17</volume>(<issue>5</issue>):<fpage>509</fpage>&#8211;<lpage>516</lpage>. doi:<pub-id pub-id-type="doi">10.1097/ADM.0000000000001189</pub-id><pub-id pub-id-type="pmid">37788601</pub-id><pub-id pub-id-type="pmcid">PMC10547105</pub-id></mixed-citation></ref><ref id="cit0069"><label>69.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Chambers</surname><given-names>LC</given-names></string-name>, <string-name name-style="western"><surname>Hallowell</surname><given-names>BD</given-names></string-name>, <string-name name-style="western"><surname>Zullo</surname><given-names>AR</given-names></string-name>, et al. <article-title>Buprenorphine dose and time to discontinuation among patients with opioid use disorder in the era of fentanyl</article-title>. <source><italic toggle="yes">JAMA Netw Open</italic></source>. <year>2023</year>;<volume>6</volume>(<issue>9</issue>):<fpage>e2334540</fpage>. doi:<pub-id pub-id-type="doi">10.1001/jamanetworkopen.2023.34540</pub-id><pub-id pub-id-type="pmid">37721749</pub-id><pub-id pub-id-type="pmcid">PMC10507490</pub-id></mixed-citation></ref><ref id="cit0070"><label>70.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Farrell</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Shahbazi</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Byrne</surname><given-names>M</given-names></string-name>, et al. <article-title>Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence</article-title>. <source><italic toggle="yes">Int J Drug Policy</italic></source>. <year>2022</year>;<volume>100</volume>:<fpage>103492</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.drugpo.2021.103492</pub-id><pub-id pub-id-type="pmid">34736130</pub-id></mixed-citation></ref><ref id="cit0071"><label>71.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Andrada</surname><given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Rodriguez</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Bandalan</surname><given-names>JH</given-names></string-name>, <string-name name-style="western"><surname>Dangelo-Kemp</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Johnston</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Wilson</surname><given-names>H</given-names></string-name>. <article-title>Retention rates with monthly depot buprenorphine in general practice in Melbourne, Australia</article-title>. <source><italic toggle="yes">Aust J Gen Pract</italic></source>. <year>2022</year>;<volume>51</volume>(<issue>6</issue>):<fpage>447</fpage>&#8211;<lpage>451</lpage>. doi:<pub-id pub-id-type="doi">10.31128/AJGP-07-21-6098</pub-id><pub-id pub-id-type="pmid">35637592</pub-id></mixed-citation></ref><ref id="cit0072"><label>72.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>MacDonald</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Connor</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Edwards</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Hardy</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Kemp</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Johnston</surname><given-names>L</given-names></string-name>. <article-title>Real-world retention rates with a long-acting buprenorphine depot in opioid-dependent patients attending private clinics in Australia</article-title>. <source><italic toggle="yes">Heroin Addict Relat Clin Probl</italic></source>. <year>2022</year>;<volume>24</volume>(<issue>2</issue>):<fpage>19</fpage>&#8211;<lpage>25</lpage>.</mixed-citation></ref><ref id="cit0073"><label>73.</label><mixed-citation publication-type="journal"><string-name name-style="western"><surname>Marsden</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kelleher</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Gilvarry</surname><given-names>E</given-names></string-name>, et al. <article-title>Superiority and cost-effectiveness of monthly extended-release buprenorphine versus daily standard of care medication: a pragmatic, parallel-group, open-label, multicentre, randomised, controlled, phase 3 trial</article-title>. <source><italic toggle="yes">EClin Med</italic></source>. <year>2023</year>;<volume>66</volume>:<fpage>102311</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.eclinm.2023.102311</pub-id><pub-id pub-id-type="pmcid">PMC10692661</pub-id><pub-id pub-id-type="pmid">38045803</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>